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The	  objectives	  of	  this	  study	  were	  to	  evaluate	  the	  incidence	  and	  outcome	  of	  critically	  ill	  
patients	  receiving	  renal	  replacement	  therapy	  (RRT)	  for	  acute	  kidney	  injury	  (AKI),	  and	  
to	   assess	   factors	   associated	   with	   outcome.	   The	   practices	   to	   provide	   RRT	   in	   Finnish	  
intensive	   care	   units	   (ICUs)	   were	   described.	   Additionally,	   the	   quality	   of	   published	  
pharmacokinetic	  studies	  in	  patients	  with	  continuous	  RRT	  (CRRT)	  was	  studied.	  	  
Materials	  and	  methods	  
Study	   I	   was	   a	   systematic	   literature	   review	   including	   49	   original	   publications	   that	  
reported	  the	  pharmacokinetic	  results	  of	  adult	  critically	  ill	  patients	  receiving	  CRRT.	  The	  
general	  quality	  of	  the	  studies	  was	  assessed	  with	  the	  Downs	  and	  Black	  Index	  score,	  and	  
the	  adequacy	  of	   the	  reporting	  of	   the	  CRRT-­‐related	  parameters	  was	  assessed	  with	   the	  
Acute	  Dialysis	  Quality	  Initiative	  minimal	  reporting	  criteria.	  	  
Altogether	  25	  200	  patients	  were	  included	  in	  studies	  II-­‐IV.	  Data	  on	  all	  admissions	  in	  
the	  24	  member-­‐ICUs	  of	  the	  Finnish	  Intensive	  Care	  Consortium	  between	  2007	  and	  2008	  
were	   obtained	   and	   included	   in	   the	   incidence	   calculations.	   Of	   the	   24	   904	   patients	  
included	  in	  study	  II,	  1686	  received	  RRT	  for	  AKI.	  Their	  hospital	  and	  6-­‐month	  mortality	  
and	   health-­‐related	   quality	   of	   life	   (HRQOL)	   were	   compared	   to	   the	   23	   218	   patients	  
without	   RRT.	   In	   study	   III,	   1558	   RRT-­‐treated	   patients	   from	   the	   same	   dataset	   were	  
divided	   according	   to	   treatment	   in	   1)	   small	   or	   large	   ICUs	   and	   2)	   ICUs	   classified	   into	  
tertiles	   according	   to	   annual	   case	   volume	   of	   RRT-­‐treated	   patients.	   The	   crude	   and	  
adjusted	   mortality	   rates	   were	   compared	   in	   these	   groups.	   Study	   IV	   was	   part	   of	   the	  
prospective,	  observational,	  FINNAKI	  cohort	  study,	  conducted	  in	  17	  Finnish	  ICUs	  during	  
a	   five-­‐month	   period.	   The	   data	   of	   296	   RRT-­‐treated	   patients	   were	   used	   to	   analyze	  
characteristics	   of	   the	   RRT	   and	   factors	   associated	  with	   90-­‐day	  mortality	  with	   special	  
emphasis	  on	  fluid	  balance	  prior	  to	  RRT	  initiation.	  	  
Main	  results	  
The	   general	   quality	   of	   pharmacokinetic	   studies	   on	   CRRT-­‐receiving	   patients	   was	  
moderate.	  The	  reporting	  of	  CRRT	  and	  patient	  characteristics	  was	  poor	  according	  to	  the	  
criteria	  by	  Acute	  Dialysis	  Quality	   Initiative,	  while	  the	  retrospectively	  calculated	  CRRT	  
dose	  in	  these	  studies	  was	  mainly	  according	  to	  the	  recommendations.	  	  
In	   study	   II,	   the	  population-­‐based	   incidence	  of	  RRT	   for	  AKI	  was	  20.2	  per	  100	  000	  
adults	  per	  year.	  The	  hospital	  mortality	  of	  RRT-­‐treated	  patients	  was	  35.0%	  and	  the	  6-­‐
month	  mortality	  was	  49.4%.	  Patients	  with	  RRT	  perceived	  their	  HRQOL	  to	  be	  as	  good	  as	  
those	   without	   at	   six	   months.	   In	   study	   III,	   patients	   treated	   in	   small	   ICUs	   had	   higher	  
crude	  and	  adjusted	  hospital	  mortality	  rates	  compared	  to	  those	  treated	  in	  large	  ICUs.	  In	  
study	  IV,	   the	  90-­‐day	  mortality	  of	  RRT-­‐treated	  patients	  was	  39.2%.	  Patients	  with	  fluid	  
overload	  at	  RRT	  initiation	  had	  twice	  as	  high	  crude	  90-­‐day	  mortality	  rate	  than	  patients	  
without,	  and	  the	  difference	  remained	  after	  adjusting	  for	  patient	  age,	  severity	  of	  illness,	  
presence	  of	  sepsis,	  time	  from	  ICU	  admission	  to	  RRT	  initiation,	  and	  initial	  RRT	  modality.	  
RRT	  was	  initiated	  after	  a	  median	  of	  14	  hours	  from	  ICU	  admission	  in	  the	  presence	  of	  a	  
 
 10	  
median	   of	   three	   indications.	   In	   73%	   of	   patients,	   the	   initial	   RRT	   modality	   was	  
continuous.	  The	  CRRT	  dose	  adjusted	  for	  daily	  duration	  of	  treatment	  was	  27.9	  mL/kg/h.	  
	   	  
Conclusions	  
The	  reporting	  of	  CRRT-­‐related	  parameters	  in	  pharmacokinetic	  studies	  was	  inadequate.	  
The	  hospital,	  90-­‐day,	  and	  6-­‐month	  mortality	   rates	  of	  patients	  with	  RRT	   for	  AKI	  were	  
high	  compared	  to	  other	  ICU-­‐treated	  syndromes,	  but	  lower	  than	  previously	  reported	  for	  
patients	   with	   RRT.	   Patients	   treated	   in	   small	   central	   hospitals	   demonstrated	   higher	  
crude	   and	   adjusted	   hospital	   mortality	   rates	   compared	   to	   those	   treated	   in	   larger	  
hospitals.	  Fluid	  overload	  at	  RRT	  initiation	  was	  associated	  with	  an	  increased	  risk	  for	  90-­‐
day	  mortality.	  RRT	  was	  initiated	  early	  after	  ICU	  admission.	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The	   first	   descriptions	   of	   renal	   failure	   treated	   with	   dialysis,	   or	   renal	   replacement	  
therapy	  (RRT),	  date	  back	  to	  1960.218	  The	  continuous	  RRT	  technique	  was	  subsequently	  
introduced,	   in	   1977,	   first	   performed	   via	   an	   arteriovenous	   circuit.130	   Later,	   safer	   and	  
more	   efficient	   venovenous	   techniques	   became	   the	   standard	   of	   care.	   During	   the	   last	  
decades,	  these	  techniques	  have	  greatly	  improved	  and	  knowledge	  regarding	  the	  optimal	  
practice	   of	   RRT	   has	   increased.	   Meanwhile,	   the	   concept	   of	   acute	   renal	   failure	   has	  
evolved	   to	   encompass	   a	   syndrome,	   acute	   kidney	   injury	   (AKI),	   defined	   by	   a	   sudden	  
decrease	   in	   the	   glomerular	   filtration	   rate	   (GFR).160	   Until	   recently,	   however,	   over	   35	  
different	   definitions	   for	   AKI	   have	   complicated	   the	   diagnostics,	   patient	   care,	   and	  
research.123	   The	   publication	   of	   Risk,	   Injury,	   Failure,	   End-­‐Stage,	   Loss-­‐of-­‐function	  
(RIFLE)	   criteria19	   and	   Acute	   Kidney	   Injury	  Network	   (AKIN)	   criteria160	   has	   facilitated	  
research	   in	   this	   field.	   Kidney	   Diseases:	   Improving	   the	   Global	   Outcomes	   (KDIGO)	   –
foundation	   recently	  published	  an	  update	   to	   these	   criteria.120	   Severe	  AKI	   treated	  with	  
RRT	   is	   associated	  with	   severe	   sepsis	   in	   about	   half	   of	   the	   patients.231	   Other	   common	  
underlying	   conditions	   include	   major	   surgery,	   hypovolemia,	   hypoperfusion,	   and	  
exposure	  to	  nephrotoxic	  agents.231	  	  
The	  population-­‐based	  incidence	  of	  RRT	  for	  AKI	  has	  varied	  from	  4	  to	  96	  per	  100	  000	  
adults	  per	  year36,242	  with	  a	  	  rising	  trend.242	  The	  incidence	  rate	  is	  broadly	  comparable	  to	  
the	   incidence	   of	   acute	   respiratory	   distress	   syndrome.209	   The	   population-­‐based	  
incidence	  of	  RRT	   for	  AKI	   in	  Finland	   is	  unknown.	  Among	  all	   intensive	   care	  unit	   (ICU)	  
patients,	  3	   to	  8%	  have	  been	  reported	   to	   receive	  RRT	   for	  AKI.55,231,196	  Patients	   treated	  
with	  RRT	  for	  AKI	  have	  high	  short-­‐term	  mortality,	  up	   to	  over	  60%,230	  which	   is	  among	  
the	  highest	  of	  all	  patient	  groups	  treated	  in	  the	  ICU.	  Previous	  assessments	  regarding	  the	  
mortality	   rates	   of	   these	   patients	   in	   Finland	   have	   been	   single-­‐center	   studies,	  
however.128,258	  The	  health-­‐related	  quality	  of	  life	  of	  RRT-­‐treated	  patients	  has	  been	  found	  
to	  be	  impaired	  compared	  to	  the	  general	  population	  after	  long-­‐term	  follow	  up.258	  Thus,	  
despite	   recent	   advances	   in	   RRT,	   the	   mortality	   rate	   remains	   strikingly	   high,	   and	  
improvements	  in	  the	  care	  of	  these	  patients	  would	  be	  essential.	  
RRT	   among	   the	   critically	   ill	   is	   a	   complex	   treatment.	   The	   results	   of	   treatment	   of	  
several	  other	  complex	  procedures,	  such	  as	  highly	  technical	  surgery21	  and	  percutaneous	  
coronary	   interventions96	   have	   been	   found	   to	   be	   better	   in	   centers	   with	   a	   high	   case	  
volume	  of	   these	  patients.	  Some	  reports	  have	  suggested	  a	  volume-­‐outcome	  effect	  also	  
among	   ICU	   patients	   with	   mechanical	   ventilation116	   and	   severe	   sepsis.192	   Regarding	  
patients	   with	   RRT,	   no	   volume-­‐outcome	   effect	   was	   found	   in	   a	   large	   cohort	   study,	   in	  
which	   ICUs	   participated	   on	   a	   voluntary	   basis.174	   Previously,	   among	   Finnish	   surgical	  
patients	  with	   severe	   sepsis,	   hospital	   survival	  was	   found	   to	  be	  better	   in	   ICUs	  of	   large	  
central	  hospitals	  or	  university	  hospitals	  compared	  to	  small	  central	  hospitals.202	  	  
The	  optimal	  time	  to	  initiate	  RRT	  is	  unclear.	  Two	  meta-­‐analyses	  have	  concluded	  that	  
early	   RRT	   initiation	   might	   be	   beneficial,118,	   219	   however,	   the	   definition	   of	   “early”	  
remains	  obscure.	  The	  only,	  small,	  randomized	  controlled	  trial	  investigating	  the	  timing	  
of	  RRT	  did	  not	   find	   early	  RRT	   to	  be	  beneficial.26	  Among	   critically	   ill	   children,	   a	   clear	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association	  of	  the	  presence	  of	  a	  high	  degree	  of	  fluid	  accumulation	  at	  RRT	  initiation	  with	  
adverse	   outcome	   has	   been	   reported.89,227	   In	   critically	   ill	   adults,	   some	   studies	   have	  
shown	  an	  association	  between	  higher	  degree	  of	   fluid	  accumulation	  24h	  prior	   to	  RRT	  
initiation16	  and	  three	  days	  preceding	  a	  nephrologist	  consultation25	  with	  increased	  risk	  
for	   mortality.	   More	   evidence	   is	   urgently	   needed,	   but	   optimizing	   the	   timing	   of	   RRT	  
initiation	   in	   relation	   to	   fluid	   accumulation,	   or	   using	   a	   more	   restrictive	   fluid	  
management	  strategy	  could	  be	  potential	  means	  to	  improve	  the	  care	  of	  these	  patients.	  	  
As	   continuous	   RRT	   is	   the	   predominantly	   used	   RRT	   modality,	   and	   half	   of	   the	  
patients	   suffer	   from	   sepsis,231	   adequate	   dosing	   of	   antimicrobial	   drugs	   is	   important.	  
Among	   patients	   with	   CRRT,	   empirical	   dosing	   strategies	   have	   been	   found	   to	   lead	   to	  
insufficient	   antibiotic	   concentrations.207	   The	   reporting	   of	   pharmacokinetic	   studies	   in	  
CRRT-­‐receiving	  patients	  has	  been	   found	   to	  be	   inadequate,141	   and	   individualized	  drug	  
dosing	   is	   recommended.44	   The	   adequacy	   of	   the	   delivered	   CRRT	   dose	   used	   in	   the	  
pharmacokinetic	   studies	   has	   not	   been	   evaluated,	   however.	   Evidently,	   ensuring	   the	  
right	  dosing	  of	  antimicrobials	   in	  this	  complex	  patient	  group	  would	  be	  another	  way	  to	  
provide	  better	  treatment.	  	  
The	   aim	  of	   this	   study	  was	   to	   evaluate	   the	   population-­‐based	   incidence	   of	  RRT	   for	  
AKI	   in	   Finland	   and	   the	   outcomes	   of	   these	   critically	   ill	   patients	   with	   RRT	   in	   two	  
nationwide	   cohorts.	   Furthermore,	   the	  potential	   existence	  of	   a	   volume-­‐outcome	  effect	  
and	  the	  association	  of	  fluid	  overload	  at	  RRT	  initiation	  with	  outcome	  were	  investigated.	  
Additionally,	   the	   quality	   of	   published	   pharmacokinetic	   reports	   in	   CRRT-­‐receiving	  
patients	  and	  the	  adequacy	  of	  the	  CRRT	  dose	  were	  evaluated.	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2. REVIEW OF THE LITERATURE 
2.1 DEFINITIONS 
2.1.1 KIDNEY FUNCTION 
Glomerular	   filtration	   rate	   (GFR)	   is	   the	   best	   measure	   of	   filtering	   capacity	   of	   the	  
kidneys,121	   and	   thus	   kidney	   function.	   GFR	   describes	   the	   amount	   of	   plasma-­‐like	   fluid	  
filtered	  through	  the	  glomerular	  capillaries	  into	  the	  renal	  tubules	  in	  a	  unit	  of	  time.	  	  
	  
GFR	  (mL/min)	  	  =	  	  	  Cu	  x	  Qu	  
	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Cp	  
	  
Cu	  =	  concentration	  of	  a	  substance	  mg/mL	  in	  urine	  
Cp=	  concentration	  of	  a	  substance	  mg/mL	  in	  (arterial)	  plasma	  
Qu=urine	  flow	  rate	  (mL/min)	  
	  
Substances	   that	   are	   freely	   filtered	   through	   glomeruli	   and	   neither	   secreted	   nor	  
reabsorbed	  can	  be	  used	  to	  measure	  GFR.	  The	  renal	  clearance	  of	  such	  substances	  equals	  
GFR.194	   The	   gold	   standard	   of	   measuring	   GFR	   is	   inulin	   clearance,194	   but	   various	  
isotopes195	   and	   iohexol31	   are	   also	   reliable.	   In	   clinical	   practice,	   the	   use	   of	   exogenous	  
substances	   to	   measure	   GFR	   is	   impractical,	   and	   creatinine	   clearance	   (CrCl)	   is	   widely	  
accepted	   as	   a	   surrogate	   marker	   for	   GFR.119	   Since	   creatinine	   is	   also	   excreted	   in	   the	  
proximal	   tubule,	   use	   of	   CrCl	   is	   prone	   to	   bias.194	   Creatinine	   excretion	   rate	   is	  
proportional	  to	  the	  serum	  concentration	  of	  creatinine,	  which	  causes	  overestimation	  of	  
GFR.194	   Serum	   and	   plasma	   concentrations	   of	   creatinine	   have	   been	   shown	   to	  
correspond.158	   Serum	   creatinine	   is	   related	   to	   age,	   gender,	   muscle	   mass,	   nutritional	  
status,138	  and	  fluid	  status.194	  	  
CrCl	   can	   be	  measured	   by	   collecting	   daily	   urine	   and	   determining	   the	   plasma	   and	  
urine	  creatinine	  concentrations.63	  Several	  equations	  have	  been	  developed	  to	  estimate	  
CrCl	   or	   GFR	   from	   serum	   creatinine	   and	   other	   factors,	   the	   Cockcroft-­‐Gault	   equation53	  
being	  the	  oldest.	  The	  ”Modification	  of	  Diet	  in	  Renal	  Disease”	  (MDRD)	  formula137	  can	  be	  
used	   to	   estimate	   GFR	   normalized	   to	   body	   surface	   area	   in	   adults.	   From	   the	   original	  
MDRD	   equation,	   an	   abbreviated	   equation	   without	   serum	   albumin	   and	   blood	   urea	  
nitrogen	   values	   is	   usually	   used.121	   The	   most	   recently	   developed	   CKD-­‐EPI	   equation	  
accounts	  for	  age,	  gender	  and	  race.139	  
 
Cockroft-­‐Gault	  equation:53	  
CrCl	  (mL/min)	  =	  (140-­‐Age)	  x	  Weight	  	  	  x	  (0.85	  if	  female)	  




MDRD	  equation	  (abbreviated	  “four	  variable	  equation”):121	  	  
GFR	  (mL/min/1.73m2)	  =	  186	  x	  SCr	  (-­‐1.154)	  x	  Age(-­‐0.203)	  x	  (0.742	  if	  female)	  x	  (1.212	  if	  Afro-­‐
American)	  
CKD-­‐EPI	  equation:139	  
GFR	  (mL/min/1.73m2)	  =	  141	  x	  min(SCr/κ,	  1)α	  x	  max(SCr/κ,	  1)-­‐1.209	  x	  0.993Age	  	  x	  	  (1.018	  
if	  female)	  x	  (1.159	  if	  Afro-­‐American)	  
	  
SCr=	  serum	  creatinine	  (mg/dL)	  
	  
κ	  =	  0.7	  if	  female	  
κ	  =	  0.9	  if	  male	  
α	  =	  -­‐0.329	  if	  female	  
α	  =	  -­‐0.411	  if	  male	  	  
min	  =	  the	  minimum	  of	  SCr/κ	  or	  1	  
max	  =	  the	  maximum	  of	  SCr/κ	  or	  1	  
	  
The	   accuracy	   of	   Cockcroft-­‐Gault	   and	   MDRD	   equations	   to	   estimate	   GFR	   within	   a	  
30%	  range	  of	   the	  measured	  GFR	  has	  been	  evaluated.121	  The	  Cockcroft-­‐Gault	  equation	  
was	  found	  to	  fulfill	  this	  limit	  in	  a	  median	  of	  75%	  of	  measurements,	  while	  over	  90%	  of	  
measurements	   were	   found	   to	   be	   within	   the	   range	   when	   the	   MDRD	   equation	   was	  
used.121	   The	   CKD-­‐EPI	   equation	   performed	   better	   in	   estimating	   GFR	   than	   the	   MDRD	  
equation	  especially	  at	  higher	  GFR	  values	  in	  its	  validation	  study.139	  A	  systematic	  review	  
confirmed	  this	  result,	  however	  it	  also	  found	  that	  the	  MDRD	  equation	  performed	  better	  
in	   estimating	   lower	   GFR	   levels	   (<60	   mL/min/1.73m2).70	   The	   Acute	   Dialysis	   Quality	  
Initiative19	  recommends	  the	  use	  of	  the	  MDRD	  equation.	  	  
Normal	  GFR	  ranges	  from	  90	  to	  130	  mL/min/1.73m2,	  mildly	  decreased	  from	  60	  to	  
89,	  moderately	  decreased	   from	  30	   to	  59,	   severely	  decreased	   from	  15	   to	  29	  and	  end-­‐
stage	  renal	  disease	  <15.121	   In	  clinical	  practice,	  a	  sudden	  decrease	  in	  urine	  output	  also	  
serves	  as	  a	  surrogate	  marker	  for	  decreased	  GFR.119	  	  
2.1.2 ACUTE KIDNEY INJURY  
Acute	   kidney	   injury	   (AKI)	   refers	   to	   a	   syndrome	   defined	   by	   an	   abrupt	   decrease	   in	  
kidney	  function.160	  AKI	  encompasses	  a	  range	  of	  patients,	  from	  those	  experiencing	  only	  
a	   minor	   decrease	   in	   GFR	   to	   those	   requiring	   renal	   replacement	   therapy	   (RRT).	   AKI	  
patients	  demonstrate	  an	  increased	  mortality	  compared	  to	  patients	  without	  AKI.39,105	  
An	   acute	   deterioration	   of	   kidney	   function	   has	   been	   defined	   in	   more	   than	   35	  
different	  ways	   in	   the	   literature,123	  which	  has	   complicated	  diagnostics,	   treatment,	   and	  
research.	  The	  Acute	  Dialysis	  Quality	  Initiative	  published	  the	  Risk,	  Injury,	  Failure,	  Loss,	  
End-­‐stage	   disease	   (RIFLE)	   criteria	   based	   on	   changes	   in	   serum	   creatinine	   and	   urine	  
output.19	   Later,	   the	   Acute	   Kidney	   Injury	   Network	   (AKIN)	   published	   the	   AKIN	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classification	  with	  slight	  modifications	  to	  RIFLE,	  and	  proposed	  the	  definition	  of	  AKI	  to	  
cover	   acute	   renal	   failure,	   acute	   tubular	   necrosis,	   and	   related	   diagnoses.160	   Both	  
classifications	   have	   been	   validated	   in	   over	   500	   000	  patients.120	  When	   the	  RIFLE	   and	  
AKIN	  classifications	  were	   compared	   in	   the	   same	  cohort,	  RIFLE	   failed	   to	   find	  patients	  
with	   AKIN	   stage	   1	   AKI,	   whereas	   AKIN	   did	   not	   identify	   patients	   with	   RIFLE	   risk	   or	  
failure	   AKI.111	   Patients	   defined	   as	   having	   AKI	   using	   either	   of	   the	   classifications	   had	  
increased	  mortality	   compared	   to	   patients	  without	   AKI.111	   The	   disparity	   between	   the	  
classifications	   further	   advocated	   the	  development	  of	   a	  new	  AKI	  definition	   combining	  
the	  two	  previous	  classifications.120	  	  All	  three	  classifications	  are	  presented	  in	  Table	  1.	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AKIN; Acute Kidney Injury Network; KDIGO; Kidney Disease: Improving Global Outcome; RIFLE; Risk, 
Injury, Failure, Loss, End-stage; RRT; renal replacement therapy; SCr; serum creatinine in µmol/L. 
The class/stage is based on worst of either SCr or urine output criteria. Urine output criteria are 
identical for RIFLE and AKIN.  
RIFLE: AKI should be abrupt (within 1-7 days) and sustained (over 24 hours).  
AKIN: Increase in SCr must occur <48 hours.  
KDIGO: Increase in SCr to ≥1.5 times baseline, which is known or presumed to have occurred within 
prior 7 days, increase in SCr ≥26.5 µmol/L within 48 hours.  
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2.2 EVALUATION AND TREATMENT OF ACUTE KIDNEY 
INJURY 
The	   causes	   for	   AKI	   are	   traditionally	   classified	   into	   prerenal,	   intrinsic	   renal,	   and	  
postrenal.	   Prerenal	   causes	   include	   factors	   leading	   to	   renal	   hypoperfusion	   and	  
decreased	   GFR	   in	   an	   otherwise	   intact	   kidney,	   such	   as	   systemic	   hypotension	   and	  
hypovolemia	  in	  septic	  shock.	  Intrinsic	  causes	  refer	  to	  processes	  affecting	  the	  structures	  
of	   the	   kidney.	   Toxins	   (e.g.	   radio	   contrast	   agents,	   aminoglycosides,	   or	   peptidoglycan	  
antibiotics)	   or	   ischemia	   may	   cause	   acute	   tubular	   necrosis.	   Other	   intrinsic	   causes	  
include	  acute	  glomerulonephritis,	   acute	   interstitial	  nephritis,	   or	   vascular	   causes	   such	  
as	  vasculitis.	  Postrenal	  causes	  refer	  to	  obstruction	  on	  the	  level	  of	  the	  collecting	  system,	  
or	  bladder	  and	  ureters.135	  The	  most	   common	  underlying	  conditions	  of	  AKI	  are	   septic	  
shock,	  cardiogenic	  shock,	  hypovolemia,	  and	  major	  surgery.231	  	  
In	   brief,	   the	   initial	   evaluation	   of	   AKI	   should	   include	   assessment	   of	   potential	  
underlying	  causes	  for	  AKI	  and	  aiming	  therapeutic	  measures	  to	  prevent	  the	  worsening	  
of	  or	  reversing	  the	  abnormalities.100	  The	  core	  of	  treatment	  of	  AKI	  according	  to	  expert	  
panels28,120	   consists	   of	   avoiding	   nephrotoxic	   drugs,	   optimizing	   hemodynamics	   and	  
volume	  status,	  preventing	  further	  injury,	  and	  in	  severe	  cases,	  RRT.	  In	  clinical	  practice,	  
furosemide	  is	  often	  tried	  after	  volume	  resuscitation,	  however,	  it	  is	  only	  recommended	  
for	  managing	  volume	  overload.120	  	  
The	   search	   for	   pharmacological	   interventions	   to	   prevent	   or	   treat	   AKI	   has	   been	  
vigorous	   but	   results	   remain	   disappointing.100	   Low-­‐dose	   dopamine,	   fenoldopam,	   or	  
atrial	  natriuretic	  peptide	  are	  not	  recommended	  to	  prevent	  or	  treat	  AKI.120	  Furosemide	  
is	   also	   not	   beneficial	   in	   the	   prevention	   of	   AKI.101	   The	  most	   recent	   promising	   results	  
come	  from	  septic	  AKI	  patients	  treated	  with	  alkaline	  phosphatase.199	  The	  most	  common	  
etiological	   factors	  are	   thought	   to	   lead	   to	  decreased	  renal	  blood	   flow,	  however,	  as	   the	  
treatment	   strategies	   aiming	   at	   increasing	   the	   renal	   blood	   flow	   have	   failed,	   the	  
approach	  may	  be	  wrong	  and	  even	  harmful.38	  Instead	  of	  increasing	  the	  work	  load	  of	  the	  
injured	   kidney	   by	   fluid	   challenges	   and	   diuretics,	   a	   concept	   of	   “permissive	  
hypofiltration”	   has	   been	   proposed.38	   The	   strategy	   is	   analogous	   to	   the	   treatment	   of	  
acute	   respiratory	   distress	   syndrome	   and	   acute	   myocardial	   infarction,	   where	   an	  
essential	  part	  of	  the	  treatment	  is	  to	  allow	  the	  injured	  organ	  to	  rest.38	  To	  rest	  the	  kidney,	  
RRT	  should	  be	  provided	  early.38	  	  
2.3 INCIDENCE OF RENAL REPLACEMENT THERAPY 
FOR ACUTE KIDNEY INJURY 
The	  annual	  population-­‐based	  incidence	  of	  AKI	  defined	  by	  RIFLE	  has	  been	  reported	  to	  
vary	  from	  181	  to	  290	  per	  100	  000	  per	  year2,36	  and	  the	  population-­‐based	  incidence	  for	  
RRT	   for	  AKI	   from	  4	   to	  96	  per	  100	  000	  per	  year	   (Table	  2).	  The	  highest	   incidence	  has	  
been	   reported	   in	   the	  United	  States	   from	  a	   community	  with	  an	  unrestricted	   access	   to	  
intensive	  care,	  where	   the	   incidence	  of	  acute	   lung	   injury	  was	  also	  higher	  compared	  to	  
other	   reports.36	  The	  population-­‐based	   incidence	  of	  RRT	   for	  AKI	   is	   comparable	   to	   the	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incidence	  of	  acute	  respiratory	  distress	  syndrome	  that	  has	  been	  reported	  to	  range	  from	  
13.5	  to	  58.7	  per	  100	  000	  per	  year.149,209	  	  	  
The	   incidence	   of	   RRT	   for	   AKI	   has	   been	   rising	   over	   the	   years;	   in	   a	   register-­‐based	  
study	   it	   rose	   from	   4	   per	   100	  000	   in	   1988	   to	   27	   per	   100	   000	   in	   2002.242	   Several	  
potential	  explanations	  for	  the	  rising	  trend	  in	  the	  incidence	  of	  RRT	  for	  AKI	  can	  be	  found.	  
First,	   although	  no	  data	  of	   the	  population-­‐based	   incidence	  of	  AKI	  of	   any	  severity	  over	  
time	  exist,	  it	  is	  likely	  to	  have	  increased.	  In	  line	  with	  this,	  the	  proportion	  of	  ICU	  patients	  
with	  AKI	  has	  been	  shown	  to	   increase	  over	   time.11	  Second,	   the	  availability	  of	  RRT	  has	  
improved.	  
Of	  all	  ICU	  patients,	  3.3%	  to	  8.3%	  have	  been	  reported	  to	  receive	  RRT	  for	  AKI	  (Table	  
2).	   	   In	   the	   multinational	   Beginning	   and	   Ending	   Supportive	   Therapy	   for	   the	   Kidney	  
(BEST)	   -­‐study,231	   the	   proportion	   of	   patients	   in	   different	   countries	   with	   acute	   renal	  
failure,	  of	  whom	  approximately	  two	  thirds	  received	  RRT,	  ranged	  from	  2.1%	  to	  22.1%.	  
The	   large	  variation	  may	   imply	  nationally	  varying	   indications	   for	  RRT.	  Of	  RRT-­‐treated	  
AKI	  patients	  14%54	   to	  40%	  (excluding	  acute-­‐on-­‐chronic	  kidney	  disease)200	  have	  been	  
reported	  to	  be	  treated	  outside	  ICUs.	  Of	  patients	  treated	   in	  the	  ICU,	  45%	  to	  98%	  have	  
received	  CRRT	  (Table	  2).	  The	  proportion	  of	  patients	  receiving	  RRT	  in	  the	  ICU	  is	  lower	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ADU; acute dialysis unit, CRRT; continuous renal replacement therapy, IRRT; intermittent 
renal replacement therapy, ICU; intensive care unit, M; multicenter, S; single center, P; 
prospective, R; retrospective, NA; not available  






2.4 RENAL REPLACEMENT THERAPY 
2.4.1 INDICATIONS 
Absolute	  indications	  	  
Generally	  accepted	  absolute	  indications	  for	  initiating	  RRT	  in	  AKI	  patients	  are	  1)	  severe	  
acidosis	   (pH	  <7.15),	   2),	   2)	   hyperkalemia	   (K>6.0	  mmol/L	   and/or	  ECG	   abnormalities),	  
and	  3)	  fluid	  overload	  (pulmonary	  edema).10,85,	  120,	  180	  In	  addition,	  uremic	  complications	  
(urea	   >36	  mmol/L	   or	   pericarditis,	   pleuritis,	   bleeding,	   encephalopathy),	   urine	   output	  
<200	  mL/12h	  or	  anuria,	  and	  hypermagnesemia	  in	  the	  absence	  of	  deep	  tendon	  reflexes	  
have	  also	  been	   listed	  as	  absolute	   indications	   for	  RRT.10	  Generally,	  before	  considering	  
RRT	  initiation	  for	  these	  indications,	  the	  patient	  has	  also	  proven	  unresponsive	  to	  other	  
treatment	  (eg.	  bicarbonate	  in	  acidosis	  or	  diuretics	  in	  fluid	  overload).10,	  120	  
The	   proportion	   of	   patients	   fulfilling	   these	   absolute	   indications	   varies.	   In	   a	  
prospective	   cohort	   study,	   10.7%	  of	  patients	  had	   severe	   acidosis,	   8.1%	  hyperkalemia,	  
30%	  fluid	  overload	  (>10%	  of	  body	  weight),	  and	  21.4%	  had	  urea	  >36	  mmol/L	  on	  RRT	  
initiation,	  which	   occurred	   a	  median	   (interquartile	   range)	   of	   1	   (0-­‐4)	   day(s)	   from	   ICU	  
admission.16	   Oliguria	   was	   present	   in	   33%	   and	   anuria	   in	   20%	   of	   patients.16	   In	   the	  
RENAL	  study,	  the	  reasons	  for	  randomization	  were	  as	  follows:	  severe	  acidosis	  (pH<7.2)	  
in	  35%,	  hyperkalemia	  (K>6.5	  mmol/L)	   in	  6-­‐9%,	  severe	  edema	  associated	  with	  AKI	   in	  
43-­‐45%,	  oliguria	   (urine	  output	  <400	  mL/day)	   in	  60%,	  urea	  >25	  mmol/L	   in	  39-­‐44%,	  
and	   creatinine	   >300	   μmol/L	   in	   39-­‐48%	   of	   patients.204	   Mean	   (+-­‐SD)	   time	   from	   ICU	  
admission	  to	  randomization	  was	  2	  (4-­‐5)	  days.204	  	  
Relative	  indications	  	  
In	  the	  absence	  of	  absolute	  indications	  for	  RRT	  in	  AKI,	  no	  consensus	  for	  RRT	  initiation	  
exists.	  As	   in	  patients	  with	  chronic	  kidney	  disease,	  a	  tendency	  to	  avoid	  RRT	  as	   long	  as	  
possible	   seems	   to	   be	   the	   current	   practice.120	   This	   is	   reasoned	   for	   the	   costs	   and	  
potential	  harm	  of	  RRT,	   the	  potential	  recovery	  of	   the	  patient	  without	  RRT,	  and	   lack	  of	  
scientific	   proof.120	   It	   is	   recommended	   to	   consider	   the	   overall	   clinical	   situation	   and	  
severity	  of	  illness,	  presence	  of	  conditions	  that	  potentially	  respond	  to	  RRT,	  the	  success	  
of	  other	  treatments	  in	  treating	  these	  conditions,	  and	  trends	  in	  the	  severity	  of	  AKI	  and	  
laboratory	   values	   rather	   than	   single	   threshold	   values.10,120,	   110,180	   Algorithms	   to	   aid	  
clinical	   decision-­‐making	   have	   been	   developed	   for	   AKI	   patients	   only,180	   and	   also	   to	  
cover	   non-­‐renal	   indications.10	   RRT	   initiation	   should	   be	   considered	   if	   AKI	   or	   general	  
illness	   severity	   is	   rapidly	  worsening	   (sustained	  oliguria	   and	  progressive	   acidosis),	   in	  
the	   presence	   of	   refractory	   fluid	   accumulation	   (and	   worsening	   pulmonary	   edema),	  
severe	  sepsis,	  hypercatabolic	   state,	  permissive	  hypercapnia,	   and	   if	   renal	   reserves	  are	  
reduced	   or	   early	   renal	   recovery	   seems	   unlikely.10,180	   The	   importance	   of	   regular	   re-­‐
evaluation	  of	  kidney	  function	  and	  the	  need	  for	  RRT	  is	  emphasized	  if	  an	  initial	  decision	  
not	  to	  start	  RRT	  is	  made.10,180	  
Optimal	  patient	  selection	  for	  RRT	  is	  complex.	  Patients	  with	  RIFLE-­‐Failure	  AKI	  not	  
receiving	  RRT	  were	  found	  to	  have	  lower	  severity	  scores	  and	  more	  frequent	  treatment	  
restrictions	  compared	  to	  RIFLE-­‐Failure	  patients	  with	  RRT.217	  Those	  without	  treatment	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restrictions	   displayed	   a	   lower	  mortality	   compared	   to	   patients	   treated	  with	  RRT,	   and	  
died	  of	  non-­‐renal	  reasons,	   implying	  that	  RRT	  would	  not	  have	  changed	  their	  course	  of	  
illness.217	  
Non-­‐renal	  indications	  
In	  the	  absence	  of	  AKI,	   indications	  for	  RRT	  include	  1)	  severe	  fluid	  overload	  to	  remove	  
fluid	   when	   diuretic	   therapy	   is	   not	   efficient	   enough	   2)	   immunomodulation	   in	   septic	  
shock	  3)	  removal	  of	  endogenous	  (eg.	  myoglobin)	  or	  ingested	  toxins	  4)	  management	  of	  
severe	   dysthermia	   or	   electrolytic	   disturbances.10	   Lithium,	   ethylene	   glycol,	   and	  
salicylates	  were	   the	  most	  common	   ingested	   toxins	  removed	  with	  hemodialysis	   in	   the	  
United	  States.103	  	  
2.4.2 BASIC PRINCIPLES AND TREATMENT MODALITIES 
Solute	   clearance	   in	   dialysis	   is	   based	   on	   diffusion.	   Diffusion	   is	   movement	   of	   solutes	  
through	  a	  semi-­‐permeable	  membrane	  in	  the	  direction	  of	  lower	  concentration	  until	  the	  
solute	   concentrations	   are	   equal	   on	   both	   sides	   of	   the	   membrane.	   The	   proportion	   of	  
solute	   concentration	   in	   the	   dialysate	   and	   in	   plasma	   is	   referred	   to	   as	   the	   saturation	  
coefficient.50	  Generally	   small	  molecules	   are	   cleared	  by	  diffusion,	   however,	   the	   size	   of	  
the	  molecules	   that	   can	  be	   cleared	  by	  diffusion	  depends	  on	   the	  pore	   size	  of	   the	   semi-­‐
permeable	   membrane.	   In	   hemofiltration,	   solute	   clearance	   occurs	   via	   convection	   (or	  
solvent-­‐drag),	  which	  is	  the	  movement	  of	  solutes	  along	  with	  the	  solvent	  across	  a	  semi-­‐
permeable	  membrane	  driven	  by	  a	  hydrostatic	  pressure	  gradient.	  Larger	  molecules,	  up	  
to	   low-­‐molecular	  weight	  proteins,	  are	  cleared	  by	  convection	  rather	   than	  by	  diffusion,	  
however,	   the	   clearance	   depends	   largely	   on	   the	   pore-­‐size	   of	   the	   membrane.140	   The	  
sieving	   coefficient	   is	   the	   proportion	   of	   solute	   concentration	   transported	   through	   the	  
membrane	  and	  concentration	  in	  plasma.50	  	  
Dialysis	   and	   other	   forms	   of	   RRT	   are	   performed	   in	   a	   closed	   circuit	   via	   a	   double-­‐
lumen	  catheter	   inserted	   in	  a	  central	  vein	  (or	   in	  ESRD	  patients,	  arteriovenous	   fistula),	  
where	   venous	   blood	   is	   pumped	   via	   the	   so-­‐called	   arterial	   line	   into	   the	   dialyzer.	   The	  
dialyzer,	   or	   filter	   in	   convective	   modalities,	   consists	   of	   hollow	   fibers	   mimicking	   the	  
capillaries	  of	  the	  kidney.	  Blood	  is	  circulated	  in	  the	  fibers	  that	  are	  separated	  by	  a	  semi-­‐
permeable	  membrane	   from	   the	   outer	   space,	  where	   the	   dialysis	   fluid	   is	   pumped	   in	   a	  
counter-­‐current	  direction.	  After	  blood	  is	  pumped	  through	  the	  dialyzer,	  it	  is	  returned	  to	  
the	   patient	   via	   the	   venous	   line	   of	   the	   catheter.	   In	   hemofiltration,	   there	   is	   no	   dialysis	  
fluid,	   but	   the	   plasma	   water	   and	   solutes	   are	   filtered	   through	   a	   semipermeable	  
membrane,	   and	   replacement	   fluid	   is	   administered	   either	   pre-­‐filter	   or	   post-­‐filter	   to	  
replace	  the	  filtered	  plasma	  water.	  	  
Intermittent	   hemodialysis	   (IHD)	   is	   the	   principally	   used	   intermittent	   RRT	   (IRRT)	  
modality.	   IHD	   sessions	   typically	   last	   from	   1.5	   to	   6	   hours.	   Other	   IRRT	  modalities	   are	  
intermittent	   hemodiafiltration,	   ultrafiltration,	   hemofiltration,	   and	   hemoperfusion.	  
Special	   techniques	   for	   non-­‐renal	   indications	   include	   plasmapheresis,	   light-­‐chain	  
dialysis,	  and	  molecular	  absorbent	  recirculating	  system	  (MARS)	   for	  acute	   liver	   failure.	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Slow	   continuous	   ultrafiltration	   and	   sustained	   low-­‐efficiency	   dialysis	   are	   so-­‐called	  
hybrid	  techniques	  between	  intermittent	  and	  continuous	  modalities.	  	  
Continuous	  RRT	  (CRRT)	  has	  been	  performed	  via	  a	  venovenous	  circuit,	  as	  described	  
above,	   since	   the	   1990s.	   CRRT	   is	   intended	   to	   run	   continuously	   throughout	   the	   day,	  
providing	   better	   hemodynamic	   stability,	   and	   slower	   shifts	   in	   fluid	   and	   electrolyte	  
balance.124	  Modalities	   include	   continuous	   venovenous	   hemofiltration	   (CVVH)	   (Figure	  
1a),	   continuous	   venovenous	   hemodialysis	   (CVVHD)	   (Figure	   1b),	   and	   continuous	  
venovenous	   hemodiafiltration	   (CVVHDF)	   (Figure	   1c),	  where	   convective	   and	   diffusive	  
clearances	   are	   combined.	   Bicarbonate-­‐buffered	   dialysis	   and	   replacement	   fluids	   are	  




Figure 1. Schematic presentation of circuits of a) continuous venovenous hemofiltration with 
predilution b) continuous venovenous hemodialysis c) continuous venovenous hemodiafiltration 




In	   the	   extracorporeal	   circuit,	   blood	   is	   in	   contact	   with	   foreign	   material	   activating	  
coagulation	  pathways.	  To	  prevent	  blood	  clotting	  in	  the	  filter	  and	  to	  enable	  the	  delivery	  
of	  treatment,	  anticoagulation	  is	  usually	  needed	  both	  in	  IRRT	  and	  CRRT.	  However,	  in	  the	  
combination	  of	   critical	   illness,	  AKI,	   and	  possible	  bleeding	   risk	   -­‐increasing	   conditions,	  
such	  as	  recent	  major	  surgery	  or	   trauma,	  disseminated	   intravascular	  coagulopathy,	  or	  
uremic	  complications	  of	  AKI,	  pros	  and	  cons	  of	  anticoagulation	  need	   to	  be	  considered	  
individually.	   No	   thresholds	   for	   blood	   values	   to	   guide	   the	   decision	   have	   been	  
established.120	  	  	  
In	   IRRT,	   in	  patients	  without	   coagulation	  abnormalities,	  unfractionated	  heparin	  or	  
low-­‐molecular-­‐weight	  heparins	  (LMWH)	  are	  recommended.120	  Unfractionated	  heparin	  
and	  LMWHs	  have	  been	  found	  to	  be	  equally	  safe	  and	  efficient	   in	  patients	  with	  chronic	  
RRT.142	   In	   Europe,	   however,	   LMWHs	   are	   preferred	   due	   to	   easier	   administration	   and	  
lower	   risk	   for	   heparin-­‐induced	   thrombocytopenia	   observed	   in	   chronic	   RRT.74	   If	  
coagulation	   abnormalities	   are	   present,	   IRRT	   is	   recommend	   to	   be	   performed	  without	  
anticoagulation.120	  	  
In	  CRRT,	  the	  need	  for	  anticoagulation	  is	  continuous,	  and	  the	  patient	  is	  more	  prone	  
to	   complications	   from	   anticoagulants.	   Regional	   anticoagulation	   of	   the	   extracorporeal	  
circuit	   with	   sodium	   citrate	   has	   recently	   been	   introduced.162	   Regional	   citrate	  
anticoagulation	   has	   been	   shown	   to	   reduce	   the	   risk	   of	   bleeding	   compared	   to	  
unfractionated	   heparin20,134,167	   and	   to	   LMWH	   (nadroparin)181	   in	   RCTs.	   The	   use	   of	  
citrate	   has	   also	   been	   associated	   with	   increased	   filter	   life	   span134,167	   and	   even	   with	  
increased	  survival	  and	  renal	  recovery.181	  Thus,	  in	  the	  absence	  of	  contraindications	  for	  
citrate,	  it	  is	  suggested	  as	  the	  primary	  anticoagulation	  method	  in	  CRRT	  in	  centers	  with	  
established	  protocols	  for	  its	  use.120	  In	  the	  presence	  of	  contraindications,	  unfractionated	  
heparin	   or	   LMWH	   are	   then	   recommended.120	   Citrate	   can,	   however,	   also	   be	   used	   in	  
patients	  with	  increased	  risk	  for	  bleeding.120	  
Mehta	   et	   al.162	   first	   described	   regional	   citrate	   anticoagulation.	   Briefly,	   citrate	   is	  
infused	  in	  the	  pre-­‐filter	  arm	  of	  the	  circuit,	  where	  it	  binds	  calcium	  in	  the	  patient’s	  blood	  
thus	  inactivating	  coagulation.	  The	  citrate-­‐calcium	  complex	  is	  partly	  dialyzed	  or	  filtered,	  
and	   the	  remaining	  citrate	   returning	   to	   the	  patient	   is	  normally	   rapidly	  metabolized	   in	  
the	  muscles	  or	  liver	  into	  bicarbonate,	  and	  the	  bound	  calcium	  is	  returned	  to	  circulation.	  
Calcium	  is	  also	  substituted	  by	  a	  post-­‐filter	  infusion.	  	  
In	  severe	  liver	  failure,	  citrate	  metabolism	  in	  the	  liver	  can	  be	  decreased.129	  Aerobic	  
conditions	   in	   muscles	   needed	   to	   metabolize	   citrate	   can	   be	   also	   be	   compromised	   in	  
severe	   shock.182	   In	   both	   of	   these	   conditions,	   citrate	   accumulation	   leading	   to	  
hypocalcemia	   and	   metabolic	   acidosis	   can	   potentially	   occur.182	   In	   studies	   regarding	  
regional	   citrate	   anticoagulation,	   patients	   with	   liver-­‐failure	   have	   usually	   been	  
excluded,251	   although	   recently	   citrate	   was	   found	   to	   be	   safe	   in	   liver-­‐transplant	  
recipients	   requiring	   CRRT	   in	   a	   retrospective	   study.210	   Metabolic	   alkalosis	   is	   another	  
possible	   complication	   of	   regional	   citrate	   anticoagulation,162	   but	   in	   a	   meta-­‐analysis	  
comparing	   citrate	   to	   heparin,	   no	   significant	   difference	   in	   its	   occurrence	   was	  
detected.251	   Consequently,	   using	   regional	   citrate	   anticoagulation	   requires	   a	   strict	  
protocol	  and	  regular	  follow-­‐up	  of	  the	  plasma	  ionized	  and	  total	  calcium	  levels.182	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2.4.4 DOSE  
Generally,	  in	  medical	  practice,	  targets	  of	  a	  therapy	  should	  be	  defined	  and	  measurable.	  
Quantification	  of	  RRT	  dose	  in	  maintenance	  dialysis	   in	  ESRD	  patients	   is	  based	  on	  urea	  
kinetics	  as	  urea	   serves	  as	  a	   surrogate	  marker	   for	  other	   low-­‐molecular	  weight	   toxins:	  
urea	  Kt/V	  describes	  the	  total	  treatment	  clearance	  of	  urea	  as	  a	  fraction	  of	  body	  water,	  
where	  K	  is	  the	  dialyzer	  urea	  clearance,	  t	  the	  treatment	  time,	  and	  V	  the	  urea	  distribution	  
volume.91	  Urea	  Kt/V	   is	  well	   validated	   in	  ESRD	  patients,170	   but	   the	  model	   is	   based	  on	  
assumptions	  of	   a	  urea	   steady	   state	   in	  plasma	  and	  a	  normal	  urea	  distribution	  volume	  
that	  are	  not	  met	   in	  critically	   ill	  AKI	  patients.49,107	  While	  no	  superior	  ways	   to	  quantify	  
the	   IRRT	   dose	   in	   AKI	   patients	   exist,	   dose	   quantification	   using	   urea	   Kt/V	   is	  
recommended.120	  	  
The	  quantification	  of	  CRRT	  dose	  is	  based	  on	  urea	  kinetics	  as	  well.	  Solute	  clearance	  
is	   the	   ratio	   of	   solute	   concentration	   in	   the	   dialysate/filtrate	   and	   in	   plasma.32	   Free	  
passage	   of	   urea	   through	   the	   dialyzer/filter	  with	   a	   sieving/saturation	   coefficient	   of	   1	  
can	  be	  assumed.32	  Thus,	   the	  effluent	   flow	  rate	  normalized	  to	  patient	  body	  weight	  can	  
be	   used	   as	   a	   surrogate	   for	   urea	   clearance.208	   The	   effluent	   flow	   rate	   in	   CVVH	   is	   the	  
replacement	  fluid	  flow	  rate,	  in	  CVVHD	  is	  the	  dialysis	  fluid	  flow	  rate,	  and	  in	  CVVHDF	  is	  
the	   sum	   of	   replacement	   and	   dialysis	   fluid	   flow	   rates.	   In	   convective	   modalities	   with	  
predilution,	  the	  efficacy	  is	  reduced	  by	  about	  15%,	  since	  the	  plasma	  entering	  the	  filter	  is	  
already	  diluted.32	  	  
 
The	  dilution	  factor	  (Fd)	  can	  be	  calculated	  as	  follows:50	  
	  
Fd	  =	  Qbw	  /(Qbw+Qr)	  	  
	  
Qbw	  =	  blood	  water	  flow	  mL/h	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  (calculated	  from	  the	  blood	  flow	  rate	  multiplied	  by	  1	  -­‐hematocrit)	  
Qr	  	  =	  replacement	  fluid	  flow	  in	  mL/h	  
	  
Although	   effluent	   flow	   rate	   normalized	   to	   patient	   weight	   (mL/kg/h)	   is	   only	   a	  
surrogate	   for	   the	   true	   dose,	   it	   is	   currently	   recommended	   for	   quantifying	   the	   CRRT	  
dose,	   considering	   also	   the	   treatment	   time	   (hours	   of	   day).120	   Recently,	   urea	   and	  
creatinine	   clearance	   during	   CVVHDF	   were	   measured	   in	   patients	   with	   a	   standard	   of	  
dose	  20	  mL/kg/h	  and	  a	  high	  dose	  of	  35	  mL/kg/h.150	   	  Estimated	  urea	   clearance	   from	  
the	  amount	  of	  spent	  effluent,	  also	  considering	  predilution	  and	  treatment	  time,	  was	  15.8	  
mL/kg/h	  for	  the	  standard-­‐dose	  group	  and	  25.1	  mL/kg/h	  for	  the	  high-­‐dose	  group.	  The	  
measured,	   true	   clearance	   in	   the	   standard-­‐dose	   group	   was	   15.6	   mL/kg/h	   and	   in	   the	  
high-­‐dose	   group	   only	   23.3	   mL/kg/h,	   35%	   less	   than	   prescribed.	   True	   creatinine	  
clearance	   corresponded	   urea	   clearance	   in	   the	   standard	   group,	   but	   in	   the	   high	   dose	  
group	  it	  was	  only	  62%	  of	  the	  prescribed	  dose.	  Another	  study	  reported	  corresponding	  
results;	   the	   true	   urea	   clearance	   was	   22.3	   mL/kg/h	   for	   a	   prescribed	   dose	   of	   30	  
mL/kg/h.51	   The	   difference	   between	   estimated	   and	   true	   clearance	   of	   middle-­‐sized	  
molecules	  is	  likely	  to	  be	  even	  larger.51	  Filter	  clotting	  occurring	  over	  time	  is	  a	  potential	  
explanation	  for	  the	  gap	  between	  the	  true	  measured	  dose	  and	  the	  estimated	  dose.51,150	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2.4.5 DRUG PHARMACOKINETICS DURING RENAL REPLACEMENT 
THERAPY 
Critical	   illness	   induces	  changes	   in	  drug	  pharmacokinetics.	  The	  volume	  of	  distribution	  
(Vd)	   can	   be	   markedly	   increased	   due	   to	   volume	   load,	   leaky	   capillaries,	   and	  
hypoalbuminemia	  causing	  decreased	  protein	  binding.223	  The	  increased	  Vd	  can	  lead	  to	  
reduced	   plasma	   concentrations	   of	   especially	   hydrophilic	   drugs.223	   Only	   the	   unbound	  
fraction	  of	  a	  drug	  is	  suspected	  to	  be	  eliminated	  by	  the	  kidney	  or	  by	  RRT.131	  Hepatic	  or	  
renal	   dysfunction	   can	   reduce	   the	   amount	   of	   a	   drug	   normally	   metabolized	   and	  
eliminated	  via	  these	  pathways	  and	  cause	  shifts	  in	  the	  distribution	  between	  hepatic	  and	  
renal	   clearance.223	   RRT	   primarily	   affects	   the	   pharmacokinetics	   of	   drugs	   that	   are	  
normally	  cleared	  renally.33	  Drugs	  with	  a	  small	  Vd	  (<1.0	  L/kg),33	  and	  that	  are	  not	  highly	  
protein	  bound,	  are	  likely	  to	  be	  removed	  with	  CRRT.48	  	  
Drug	   clearance	  during	  CRRT	   is	   affected	  by	   the	  modality,	   dose,	   and	   filter/dialyzer	  
pore	   size,	   area,	   and	   age.48	   In	   addition,	   the	   Gibbs-­‐Donnan	   effect	   affects	   the	   drug	  
clearance,33	   although	   its	   clinical	   relevance	   is	   unclear.44	   Because	   negatively	   charged	  
proteins	   are	   retained	   on	   the	   blood-­‐side	   of	   the	  membrane,	   cationic	   drugs	   are	   filtered	  
slightly	   less	   than	   anionic.33	   Generally,	   CVVH	   and	   CVVHDF	   are	   more	   effective	   in	  
removing	   especially	   larger-­‐sized	   drugs	   than	   CVVHD.33,48	   Higher	   effluent	   flow	   rates	  
resulted	   in	   increased	   clearance	   of	   piperacillin-­‐tazobactam	   although	   large	   inter	  
individual	  variations	  were	  present.233	  However,	  a	  substudy	  of	  a	  multinational	  study	  did	  
not	   find	   significant	   differences	   in	   the	   concentrations	   of	   empirically	   administered	  
antibiotics	   in	  patients	   receiving	  a	  CRRT	  dose	  25	  vs.	  40	  mL/kg/h.207	  Furthermore,	   the	  
antibiotic	  concentrations	  were	  outside	  the	  targeted	  range	  25%	  of	  the	  time.207	  Patient’s	  
residual	   renal	   function	   during	   CRRT,	   although	   hard	   to	  measure,	   can	   also	   affect	   drug	  
clearance.	   Additionally,	   drug	   may	   also	   be	   adsorbed	   to	   the	   filter,191	   which	   exerts	  
saturation	  over	  time	  and	  this	  is	  not	  taken	  into	  account	  in	  drug	  dosing	  guidelines.33	  
Several	   strategies	   for	   individualized	   drug	   dosing	   during	   CRRT	   in	   the	   critically	   ill	  
have	   been	   published.33,44,212	   In	   brief,	   since	   the	   loading	   dose	   depends	   only	   on	   the	   Vd,	  
adjusting	  it	  because	  of	  CRRT	  is	  not	  necessary.212	  The	  Vd	  can	  be	  increased	  due	  to	  critical	  
illness,	   however,	   and	   previously	   published	   data	   can	   be	   used	   to	   calculate	   a	   suitable	  
loading	  dose.44	  The	  maintenance	  dose	  of	  the	  drug	  depends	  on	  the	  total	  clearance	  and	  is	  
the	  sum	  of	  non-­‐CRRT	  clearance	  and	  the	  CRRT	  clearance.44	  The	  CRRT	  clearance	  can	  be	  
calculated	  on	  the	  basis	  of	  the	  CRRT	  modality,	  dose,	  and	  from	  the	  previously	  published	  
Sc/Sd	  values.44	  A	  more	  accurate	  way	  would	  be	  to	  calculate	  the	  individual	  Sc/Sd	  values	  
for	   the	   patient	   by	  measuring	   the	   plasma	   and	   dialysate/filtrate	   concentrations.44	   The	  
non-­‐CRRT	  clearance	  can	  be	  obtained	  from	  previously	  published	  values,	  but	  other	  organ	  
failures	   such	  as	  hepatic	   failure	   should	  be	   accounted	   for.44	  Especially	   regarding	  drugs	  






In	  evaluating	  the	  outcome	  of	  ICU-­‐treated	  patients,	  using	  a	  fixed	  endpoint	  such	  as	  30-­‐	  or	  
90-­‐day	   mortality	   has	   been	   recommended.88	   Short-­‐term	   mortality	   refers	   to	   hospital	  
mortality	   or	   death	   at	   28	   or	   30	   days	   from	   ICU	   admission,	   RRT	   initiation	   or	   in	   RCTs,	  
randomization.	  Among	  critically	   ill	  patients	  with	  RRT,	  high	  and	  greatly	  varying	  short-­‐
term	   mortality	   rates	   from	   28%	   to	   80%	   have	   been	  
reported.1,12,26,35,43,45,57,59,67,72,76,128,151,152,165,169,177,179,184,187,204,211,213,221,229,230,241,243,258	   The	  
great	  variability	  may	  be	  due	  to	  varying	  patient	  populations,	  different	  inclusion	  criteria,	  
varying	   disease	   severity,	   and	   differences	   in	   used	   RRT	   modalities,	   RRT	   timing,	   and	  
dosing.	  The	  severity	  of	   illness	  measured	  with	   the	  APACHE	  III	   score	   in	   the	  study	  with	  
the	   lowest	  mortality	   rate26	  was	   lower	   than	   that	   of	   the	   RENAL	   study,	   204	   for	   instance	  
(79-­‐88	  vs.	  103).	  The	  studies	  reporting	  the	  highest	  mortality	  rates	  from	  76	  to	  80%	  have	  
been	   conducted	   in	   Brazil	   and	   Saudi-­‐Arabia.1,151	   In	   the	   BEST	   study,230	   including	   ICUs	  
from	  23	  different	   countries,	   the	  hospital	  mortality	  of	  patients	  with	  CRRT	  was	  63.8%,	  
and	  great	  differences	  between	  countries	  existed.	  	  
Data	  on	  improvement	  of	  the	  treatment	  results	  of	  RRT	  patients	  are	  conflicting.	  In	  the	  
United	  States,	  a	  register-­‐based	  cohort	  study	  that	  also	  included	  patients	  treated	  outside	  
the	   ICU,	   found	   the	  mortality	   of	  RRT-­‐treated	  AKI	  patients	   to	  decrease	  over	   time	   from	  
41%	   in	   1988	   to	   28%	   in	   2002,	   despite	   increased	   disease	   severity.242	   Another	   study	  
found	   the	   mortality	   of	   ICU	   patients	   with	   any	   severity	   of	   AKI	   to	   decrease	   over	   time	  
between	   1996	   and	   2005	   also	   after	   adjusting	   for	   covariates.11	   In	   a	   meta-­‐analysis,254	  
pooling	   studies	   among	   AKI	   patients	   with	   and	   without	   RRT	   from	   1954	   to	   2003,	  
however,	  the	  mortality	  rate	  remained	  rather	  steadily	  around	  50%.	  
  
60-­‐day	  or	  90-­‐day	  mortality	  and	  long-­‐term	  mortality	  
After	   hospital	   discharge,	   late	   mortality	   and	   morbidity	   continue	   to	   occur.4	   Studies	  
reporting	  60-­‐day	  or	  90-­‐day	  mortality	  and	  long-­‐term	  mortality	  are	  presented	  in	  Table	  3.	  
Regarding	  short-­‐term	  mortality,	  60/90-­‐day	  and	   long-­‐term	  mortality	   rates	  are	  greatly	  
varying.	   A	   cohort	   study47	   including	   only	   patients	   with	   surgical	   sepsis	   reported	   the	  
highest	  60-­‐day	  mortality	  of	  85%.	  Mortality	  rates	  at	  one	  year	  have	  varied	  from	  57%258	  
to	  76%;35	  patients	   in	   the	   study	  by	  Carl	   et	   al.35	  had	   sepsis	   and	  were	  more	   severely	   ill	  
than	   patients	   in	   the	   study	   by	   Åhlström	   et	   al.258	   After	   one	   year,	   mortality	   has	   been	  
reported	   to	   increase	   from	  57-­‐65%213,258	   to	   70-­‐75%	   at	   five	   years.214,258	   However,	   in	   a	  
large	  cohort	  study	  among	  all	  general	  ICU	  patients,	  the	  mortality	  rate	  paralleled	  the	  rate	  




Short-­‐term	  mortality	  of	  other	  ICU	  patient	  groups	  
In	   the	   general	   ICU	   population,	   hospital	   mortality	   has	   varied	   from	   11%	   to	   64%	  
depending	   on	   illness	   severity	   and	   case-­‐mix.249	   During	   the	   past	   decade,	   hospital	  
mortality	   rates	   of	   patients	  with	   severe	   sepsis	   or	   septic	   shock	   have	   been	   reported	   to	  
range	   from	   29%80	   to	   62%.73	   As	   in	   studies	   in	   patients	   with	   AKI,	   varying	   definitions,	  
patient	   populations,	   and	   treatment	   regimens	   seem	   to	   cause	   great	   variations	   in	   the	  
mortality	   rates.	  A	   systematic	   review	  studied	  mortality	   in	  acute	   lung	   injury	   and	  acute	  
respiratory	   distress	   syndrome	   from	   1994	   to	   2006	   and	   found	   an	   overall	   short-­‐term	  

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.5.2 RENAL RECOVERY 
Acute	   Dialysis	   Quality	   Initiative	   has	   defined	   the	   renal	   outcome	   after	   AKI	   either	   as	  
complete	  or	  partial	  renal	  recovery,	  or	  ESRD.19	  In	  that	  definition,	  complete	  recovery	  is	  
defined	  as	   returning	   to	  patients’	   initial	  RIFLE-­‐class	  or	  as	  GFR	  at	  hospital	  discharge	  >	  
60mL/min/1.73m2.	  Partial	   recovery	   is	  defined	  as	  a	  persistent	  change	   from	  the	   initial	  
RIFLE-­‐class	  or	  a	  GFR	  <60mL/min/1.73m2	  at	  hospital	  discharge	  without	  a	  need	  for	  RRT.	  
ESRD	   is	   defined	   as	   dependency	   on	   RRT	   after	   three	   months	   from	   the	   initial	   insult.	  
However,	   the	   study	   by	   Wald	   et	   al.245	   showed	   that	   even	   though	   patients	   were	  
discharged	  from	  hospital	  without	  a	  need	  for	  RRT,	  the	  incidence	  of	  developing	  a	  chronic	  
need	  for	  RRT	  was	  2.63	  per	  100	  person	  years	  after	  a	  median	  follow-­‐up	  of	  three	  years.	  
For	   comparison,	   the	   incidence	   for	   chronic	   RRT	   was	   0.91	   per	   100	   person	   years	   for	  
patients	   hospitalized	   for	   other	   reasons	   than	   AKI	   and	   not	   receiving	   RRT	   during	   the	  
index	   hospital	   period.245	   Thus,	   although	   patients	   may	   initially	   recover	   their	   kidney	  
function,	  AKI	  seems	  to	  be	  a	  risk	  factor	  for	  further	  development	  for	  ESRD.244	  To	  enhance	  
the	  possibility	  of	  generalizing	  between	  different	  studies,	  assessing	  renal	  recovery	  at	  90	  
days	  has	  been	  proposed.153	  	  
Renal	   recovery	   rates	   of	  RRT-­‐treated	  patients	   are	   presented	   in	  Table	   3.	   The	   renal	  
recovery	  rate	  defined	  as	  independency	  of	  RRT	  and	  measured	  after	  60	  days	  to	  5	  years	  
from	   initial	   insult	   has	   varied	   from	   62	   to	   98%	   (Table	   3).	   One	   study	   reported	   a	   renal	  
recovery	   rate	   at	   hospital	   discharge	   as	   99.5%.241	   The	   study	   by	   Prescott	   et	   al.200	   with	  
lowest	  renal	  recovery	  rate	  (62%)	  also	  included	  patients	  with	  acute-­‐on-­‐chronic	  kidney	  
disease,	  while	  87%	  of	   survivors	  with	  de-­‐novo	  AKI	   recovered.	  Patients	  with	   sepsis	  or	  
post-­‐surgical	  AKI	  recovered	  more	  often.200	  Studies	  with	  lower	  renal	  recovery	  rate	  seem	  
to	  have	  also	  lower	  mortality	  rate,	  implying	  that	  part	  of	  the	  patients	  who	  died	  in	  other	  
studies	  might	  not	  have	  recovered	  their	  renal	  function	  had	  they	  survived.153,206	  Neither	  
RRT	  modality,232,241	  nor	  dose204,	   187	  have	  been	  shown	  to	  affect	  renal	  recovery	   in	  RCTs,	  
although	   patients	   with	   CRRT	   had	   better	   renal	   recovery	   rate	   in	   a	   cohort	   study.18	  
Regarding	   biomarkers,	   plasma	   NGAL	  was	   not	   found	   to	   be	   useful	   in	   predicting	   renal	  
recovery,56	   however	   using	   a	   panel	   of	   urinary	   biomarkers	   might	   be	   useful.225	  
Furosemide	   infusion	  after	  CRRT	  cessation	   improved	  urine	  output	  volume	  but	  did	  not	  
affect	  renal	  recovery	  rate	  in	  a	  single-­‐center	  RCT.234	  
2.5.3. HEALTH-RELATED QUALITY OF LIFE  
Survivors	   of	   critical	   illness	   continue	   to	   suffer	   from	   long-­‐term	   morbidity.62	   Health-­‐
related	  quality	   of	   life	   (HRQOL)	   after	   intensive	   care	   is	   an	   important	  measure	   of	   long-­‐
term	  outcome.4	  To	  measure	  HRQOL,	  the	  Short	  form	  -­‐36	  (SF-­‐36)246	  or	  EuroQOL	  EQ-­‐5D75	  
instruments	   are	   recommended	   after	   at	   least	   six	   months	   of	   follow-­‐up.4	   Both	  
instruments	   include	   questions	   related	   to	   physical	   and	   mental	   health	   as	   well	   as	   a	  
question	   for	   assessing	   the	   overall	   health	   status,75,246	   and	   answer	   given	   by	   patient’s	  
proxy	  have	  been	  found	  to	  be	  reliable.102	  	  
	  
 29	  
A	   systematic	   review	  of	  HRQOL	   studies	   concluded	   that	   survivors	   of	   critical	   illness	  
have	   poorer	   HRQOL	   compared	   to	   the	   general	   population	   both	   at	   baseline	   (time	  
preceding	   ICU	   admission)	   and	   after	   long-­‐term	   follow	   up,	   although	  HRQOL	   improved	  
over	   time	   after	   discharge.65	   Age	   and	  high	  disease	   severity	  were	   predictors	   of	   poorer	  
HRQOL	  after	  follow-­‐up.65	  Two	  thirds	  of	  survivors	  of	  critical	  illness	  have	  reported	  their	  
own	   perception	   of	   health	   to	   be	   good	   at	   90	   days	   after	   admission.34	   Factors	   found	   to	  
predict	   poor	  HRQOL	  were	   unplanned	   admission,	   hypothermia,	  metastatic	   cancer,	   pH	  
below	   7.25,	   and	   creatinine	   >	   176	   μmol/L	   on	   admission.34	   A	   meta-­‐analysis	   among	  
survivors	  of	  acute	  respiratory	  distress	  syndrome64	  and	  a	  systematic	  review	   including	  
studies	  in	  sepsis	  patients250	  have	  shown	  that	  HRQOL	  remains	  impaired.	  
The	   HRQOL	   of	   patients	   who	   have	   received	   RRT	   during	   their	   ICU	   stay	   has	   been	  
reported	  to	  be	  impaired	  measured	  either	  with	  the	  SF-­‐36,59,176	  EQ-­‐5D,258	  Health	  Utilities	  
Index,112	  or	  the	  Nottingham	  Health	  Profile.90,	  128,	  169	  The	  HRQOL	  has	  been	  compared	  to	  
either	   previous	   normative	   values	   obtained	   from	   general	   population59,112,128,176	   or	   the	  
values	  of	  age	  and	  gender	  matched	  general	  population.258	  Problems	   in	  physical	  health	  
have	  been	  described	   in	  particular.59,258	   In	   the	  study	  by	   Johansen	  et	  al.,112	  a	  quarter	  of	  
the	   patients	   reported	   an	   extremely	   low	   HRQOL	   score	   at	   60	   days.	   In	   another	   report	  
from	  the	  same	  cohort,	  HRQOL	  was	  found	  to	  be	  a	  predictor	  of	  mortality	  at	  one	  year.113	  
Intensity	  of	  RRT	  or	  RRT	  dependency	  did	  not	  affect	  HRQOL,	  but	  longer	  hospital	  stay	  was	  
associated	   with	   worse	   HRQOL.112	   In	   contrast	   to	   these	   findings,	   Gopal	   et	   al.90	   and	  
Delanney	   et	   al.59	   have	   reported	   that	   a	  majority	   of	   patients	  would	   undergo	   the	   same	  
treatment	  again	  if	  necessary	  and	  perceived	  their	  health	  state	  as	  acceptable	  or	  good.	  	  
2.6 PATIENT-RELATED FACTORS AND MORTALITY IN 
RRT PATIENTS 
2.6.1 ADMISSION TYPE 
The	  ICU	  admission	  type	  (medical,	  scheduled	  surgical,	  unscheduled	  surgical)	  is	  included	  
in	   several	   ICU	   outcome-­‐predicting	   models.	   Unscheduled	   surgical	   admission	   is	  
associated	   with	   the	   highest	   risk	   for	   hospital	   mortality	   in	   the	   SAPS	   II	   model.136	   RRT	  
patients	  with	  surgical	  admission	  have	  been	   found	   to	  have	  an	   increased	  risk	   for	   long-­‐
term	   mortality.200,214	   In	   the	   multicenter	   BEST	   study	   the	   admission	   diagnosis	  
“respiratory	   surgery”	   was	   strongly	   associated	   with	   an	   increased	   risk	   for	   hospital	  
mortality,	  although	  surgery	  as	  a	  contributing	   factor	   to	  AKI	  decreased	   the	  risk.230	   In	  a	  
study	   that	   also	   included	   AKI	   patients	   without	   RRT,	   both	   admission	   for	   non-­‐cardiac	  
surgery	  and	  cardiac	  surgery	  compared	  to	  medical	  admission	  were	  found	  to	  reduce	  the	  
risk	   for	   one-­‐year	   mortality,13	   although	   these	   patients	   were	   probably	   at	   least	   partly	  
elective	   and	   thus	   had	  better	   prognosis.	  Need	   for	  RRT	   after	   cardiac	   surgery	  has	   been	  
found	  to	  independently	  increase	  the	  mortality	  among	  cardiac-­‐surgery	  patients.41	  Thus,	  
if	  surgery	  is	  the	  cause	  of	  AKI,	  the	  patient	  may	  have	  better	  prognosis	  than	  patients	  with	  
other	  reasons	  for	  AKI,	  but	  (non-­‐elective)	  surgical	  admission	  is	  probably	  not	  associated	  




2.6.2 SEVERITY OF DISEASE, AGE, AND CO-MORBIDITIES 
Higher	  disease	  severity	  measured	  either	  by	  APACHE	  II,12,98,211	  SAPS	  III	  on	  the	  first	  ICU	  
treatment	  day,	  152	  or	  SOFA	  score	  on	  the	  day	  of	  RRT	  initiation133,143	  has	  been	  shown	  to	  
be	   associated	  with	   higher	  mortality.	   However,	   of	   the	   general	   disease	   severity	   scores	  
(APACHE	  II,	  SAPS	  II,	  and	  Mortality	  Probability	  Model	  at	  24h	  II),	  none	  has	  proved	  to	  be	  
confident	   enough	   for	  predicting	   individual	  patients’	   outcome.77	  Recently,	   a	  model	   for	  
predicting	  60-­‐day	  mortality	  of	  RRT-­‐receiving	  patients	  was	  developed,	  however,	   it	  has	  
not	   yet	   been	   validated	   in	   other	   populations.60	   Also,	   the	   number	   of	   non-­‐renal	   organ	  
failures,17,40,151	   or	   separately	   liver	   failure,12,35,179	   respiratory	   failure	   or	   the	   need	   for	  
mechanical	  ventilation,179,230	  need	  for	  vasoactives,41,46,	  179	  hematological	  failure,35,179	  or	  
neurological	   failure179	   have	   been	   associated	   with	   increased	   risk	   for	   mortality.	   Not	  
surprisingly,	   increasing	   age,59,143,151,230	   presence	   of	   co-­‐morbidities,59,151	   and	   worse	  
functional	  status151	  have	  been	  associated	  with	  worse	  outcome.	  A	  strong	  association	  of	  
age	   and	   comorbidities	   with	   mortality	   has	   also	   been	   reported	   among	   patients	   with	  
sepsis.5	   Increased	   body	  mass	   index	   has	   been	   shown	   to	   associate	  with	   increased	   AKI	  
incidence,	   but	   if	   RRT	   was	   required,	   adjusted	  mortality	   rates	   were	   lower	   in	   patients	  
with	  body	  mass	   index	  ranging	   from	  25	  to	  35	  compared	  to	  normal-­‐	  or	  underweighted	  
patients.67	  	  	  
2.6.3 SEPSIS 
Sepsis	  has	  been	  found	  as	  an	  underlying	  cause	  of	  AKI	  in	  43	  to	  70%	  of	  patients.12,173,221,231	  
Patients	   with	   septic	   AKI	   have	   been	   reported	   to	   have	   higher	   disease	   severity	   and	  
mortality	   compared	   to	   patients	   with	   non-­‐septic	   AKI.14,173	   In	   the	   multinational	   BEST	  
study,14	   septic	  AKI	  patients	   (of	  whom	  71%	  received	  RRT)	  had	  a	  hospital	  mortality	  of	  
70%	  compared	  to	  non-­‐septic	  AKI	  patients	  with	  a	  mortality	  of	  52%.	  Septic	  patients	  had	  
a	  longer	  delay	  before	  initiation	  of	  RRT	  (a	  median	  of	  two	  days	  vs.	  one	  day)	  compared	  to	  
non-­‐septic,	   and	   time	   from	   ICU	   admission	   to	   RRT	   initiation	   was	   also	   independently	  
associated	   with	   increased	   mortality.14	   In	   the	   same	   study,	   septic	   AKI	   was	   an	  
independent	  risk	  factor	  for	  mortality	  after	  adjusting	  for	  severity	  of	  illness,	  age,	  baseline	  
kidney	  function,	  admission	  type,	  and	  country.14	  High	  60-­‐day	  mortality	  rates	  from	  68%	  
to	  85%	  have	  been	  reported	  for	  patients	  with	  septic	  shock	  and	  RRT	  with	  an	  APACHE	  II	  
score	   of	   24-­‐25.35,47	   The	   presence	   of	   sepsis	   or	   severe	   sepsis	   has	   also	   been	   associated	  




Red	  blood	  cell	  distribution	  width	  
Red	  blood	  cell	  distribution	  width	  is	  a	  marker	  in	  normal	  blood	  count	  that	  describes	  the	  
size	   variation	   of	   the	   circulating	   red	   blood	   cells.	   Processes	   related	   to	   increased	   red	  
blood	  cell	  destruction	  and	   ineffective	  erythropoiesis	   cause	  variation	   in	   red	  blood	  cell	  
distribution	   width.81	   It	   has	   been	   related	   to	   worse	   prognosis	   among	   patients	   with	  
coronary	  artery	  disease	  and	  heart	  failure,	  possibly	  because	  of	  increased	  inflammation	  
and	   malnutrition.81	   Red	   blood	   cell	   distribution	   width	   over	   the	   normal	   limit	   at	   RRT	  
initiation	   was	   associated	   after	   adjustments	   with	   an	   increased	   risk	   for	   short-­‐term	  
mortality	  in	  patients	  with	  CRRT.177	  	  
 
Novel	  biomarkers	  	  
Plasma	  neutrophil-­‐associated	   lipocalin	   (NGAL)	   is	  an	  early	  biomarker	   for	  AKI.56	   It	  has	  
been	  shown	  to	  both	  detect	  AKI	  48	  hours	  prior	  to	  clinical	  diagnosis	   in	  the	  general	  ICU	  
population	  and	  predict	   the	  need	   for	  RRT.56	  Moreover,	  plasma	  NGAL	  measured	  at	   the	  
time	   of	   RRT	   initiation	  was	   reported	   to	   predict	   28-­‐day	   survival.133	   Urinary	  NGAL	   can	  
differentiate	  between	  pre-­‐renal	  AKI	  and	  intrinsic	  AKI	  in	  patients	  with	  established	  AKI	  
already,	   and	   predict	   their	   adverse	   outcome	   (rise	   of	   RIFLE-­‐class,	   need	   for	   RRT,	   or	  
death).222	   In	   a	   meta-­‐analysis,	   both	   plasma	   and	   urine	   NGAL	   were	   found	   to	   be	   good	  
diagnostic	  markers	  and	  predictors	  both	  for	  RRT	  and	  outcome.93	  
Cystatin	  C	  measured	  in	  plasma	  can	  be	  used	  to	  diagnose	  and	  predict	  AKI,256	  but	  its	  
performance	  in	  predicting	  the	  need	  for	  RRT	  or	  mortality	  does	  not	  seem	  to	  be	  superior	  
to	  serum	  creatinine,	  blood	  urea	  nitrogen,	  or	  urine	  output.193	  Angiopoetin-­‐2	   facilitates	  
endothelial	  activation	  and	  inflammation,78	  and	  measured	  at	  RRT	  initiation,	  it	  has	  been	  
shown	  to	  be	  a	  good	  predictor	  of	  28-­‐day	  outcome	  in	  patients	  with	  RRT.132	  Osteopontin,	  
a	   cytokine,	   has	   also	   been	   suggested	   as	   a	   novel	   biomarker	   for	   predicting	   outcome	   in	  
patients	  with	  RRT.146	  	  
Micro-­‐RNAs	   regulate	   gene	   expression	   and	   circulate	   in	   plasma	   in	   a	   stable	   form,	  
which	   can	   be	   measured	   by	   quantitative	   real-­‐time	   PCR.166	   Briefly,	   deregulation	   of	  
selected	  micro-­‐RNAs	  may	   be	   disease	   specific,	   and	   cause	   changes	   in	   gene	   expression	  
ultimately	   leading	   to	   disease	   processes.228	   Plasma	   level	   of	  miR-­‐210	  was	   found	   to	   be	  
upregulated	   in	  AKI	  patients	  with	  RRT	   compared	   to	  healthy	   controls	   or	  patients	  with	  
myocardial	   infarction.147	   Elevated	   miR-­‐210	   levels	   were	   associated	   with	   28-­‐day	  
mortality,	  however,	  with	  an	  AUC	  of	  only	  0.7.147	  	  
To	   summarize,	   the	   vigorous	   search	   for	   novel	   biomarkers	   able	   to	   diagnose	   AKI	  
before	   clinical	   diagnosis,	   stratify	   the	   severity	   of	   AKI,	   predict	   the	   need	   for	   RRT,	   and	  
predict	   outcome	   is	   ongoing.	   Thus	   far,	   plasma	   NGAL	   seems	   most	   promising	   in	  
predicting	   both	   the	   need	   for	   RRT	   and	   outcome,56	   however,	   none	   of	   the	   novel	  




2.7 RENAL REPLACEMENT THERAPY -RELATED 
FACTORS AND OUTCOME 
2.7.1 TIMING 
Consensus	  exists	  neither	  on	  the	  optimal	  timing	  of	  RRT	  initiation	  for	  AKI	  nor	  on	  which	  
parameter	  is	  the	  most	  suitable	  to	  define	  “timing”.	  Apart	  from	  immediate	  indications	  for	  
RRT,	   the	   decision	   to	   initiate	  RRT	   is	  mainly	   based	   on	   clinical	   judgment.	   Recent	  meta-­‐
analyses118,	  219	  and	  a	  systematic	  review180	  concluded	  that	  early	  RRT	  might	  be	  beneficial.	  
One	  small	  RCT	  studied	  timing	  randomizing	  patients	  regarding	  time	  from	  ICU	  admission	  
into	   early	   or	   late	   CRRT,	   and	   found	   no	   survival	   benefit	   for	   the	   early	   RRT.26	   Another	  
small	  RCT	  studied	  RRT	  initiation	  as	  soon	  as	  urine	  output	  decreased	  to	  a	  level	  <30	  mL/h	  
(early)	   compared	   to	   <20	   mL/h	   (late),	   and	   found	   over	   6-­‐fold	   lower	   mortality	   in	   the	  
early	  RRT	  group.226	  	  
Bagshaw	  et	  al.16	  studied	  characteristics	  of	  patients	  at	  RRT	  initiation,	  and	  found	  that	  
patients	   with	   multiple	   triggering	   factors	   for	   RRT	   had	   higher	   mortality	   compared	   to	  
patients	  with	  few	  triggers.	  They	  also	  found	  that	  the	  longer	  time	  from	  ICU	  admission	  to	  
RRT	   initiation	   associated	   with	   increased	   risk	   for	   mortality,	   as	   reported	   also	  
previously.178	   The	   shorter	   ICU	   stay	   prior	   to	   randomization	   and	   RRT	   initiation	   in	   the	  
RENAL	  study	  compared	  to	  another	  large	  RCT187	  (2	  vs.	  4	  days)	  has	  also	  been	  suggested	  
as	  one	  possible	  explanation	  for	  the	  lower	  mortality	  in	  the	  RENAL	  study.186	  	  
As	   in	   ESRD	   patients,	   implementation	   of	   thresholds	   of	   blood	   levels	   of	   creatinine,	  
urea,	  or	  blood	  urea	  nitrogen	  (mg/dL	  can	  be	  converted	  to	  urea	  mmol/L	  multiplying	  by	  
0.357)	  has	  been	  studied	  in	  several	  observational	  cohort	  studies.	  Cut-­‐offs	  for	  blood	  urea	  
nitrogen	  between	  60	  mg/dL	  and	  100	  mg/dL	  to	  define	  early	  RRT	  have	  been	  studied,	  all	  
studies	   finding	  better	  outcome	  for	  early	  RRT.35,84,197,252	  However,	  regarding	  time	  from	  
ICU	  admission	  to	  RRT	  initiation	  in	  these	  studies,	  early	  has	  meant	  4.4	  to	  10.5	  days	  and	  
late	   11.3	   to	   19.4	   days,35,84,252	   which	   compared	   to	   a	   recent	   practice	   study	   is	   not	   very	  
early.230	  Bagshaw	  et	  al.16	  used	  a	  urea	  cut-­‐off	  of	  24	  mmol/L	  and	  creatinine	  309	  μmol/L	  
to	  define	  early	  and	  late,	  and	  found	  no	  difference	  in	  mortality.	  However,	  when	  patients	  
were	  classified	  according	   to	   time	   from	  ICU	  admission	   to	  RRT	   initiation,	  patients	  with	  
early	   (<2	  days)	  RRT	  survived	  better.16	  Moreover,	  using	  relative	  changes	  of	  creatinine	  
and	   urea	   values	   from	   ICU	   admission	   to	   RRT	   initiation,	   the	   change	   in	   urea	   was	   not	  
associated	   with	   an	   increased	   risk	   for	   hospital	   death,16	   but	   results	   regarding	   serum	  
creatinine	  values	  have	  been	  conflicting.15,16	  When	  serum	  urea	  was	  studied	  either	  as	  a	  
continuous	  variable	  or	  as	  a	  categorical	  variable	  with	  different	  cut-­‐offs,	  no	  association	  
with	  hospital	  mortality	  was	  found.58	  	  	  	  	  
The	  suitability	  of	  RIFLE	  classification	   to	  define	   timing	  of	  RRT	  has	  been	  studied	   in	  
two	   cohorts	   of	   surgical	   ICU	   patients	   using	   only	   the	   RIFLE-­‐creatinine	   criteria.47,220	  
Earlier	  RRT	  (RIFLE-­‐Risk	  or	  no	  AKI)	  was	  found	  to	  associate	  with	  better	  outcome	  among	  
gastrointestinal	   surgery	   patients.220	   This	   finding	   was	   not	   confirmed	   in	   a	   larger,	   and	  
more	  heterogeneous	  surgical	  cohort	  concluding	  that	  RIFLE	  is	  a	  poor	  tool	  for	  classifying	  
the	  timing	  of	  RRT.47	  Among	  general	  ICU	  patients	  with	  RRT,	  RIFLE	  class	  was	  not	  found	  
to	  be	  associated	  with	  mortality.151	  Moreover,	  Bagshaw	  et	  al.16	   found	  no	  association	  of	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RIFLE	  class	  (using	  both	  creatinine	  and	  urine	  output	  criteria)	  and	  mortality.	  Besides	  the	  
fact	  that	  RIFLE	  has	  not	  been	  designed	  to	  predict	  the	  outcome	  of	  patients	  with	  RRT,	  the	  
conflicting	   results	   of	   studies	  using	  only	   creatinine	   criteria	  might	  be	   explained	  by	   the	  
fact	   that	   lower	   creatinine	   at	   RRT	   initiation	   indicates	   the	   presence	   of	   more	   urgent	  
indications	   for	  RRT	   initiation	   than	   the	  accumulation	  of	  uremic	   toxins,	   e.g.	   acidosis	  or	  
volume	  overload	  and	  the	  subsequent	  increased	  volume	  of	  creatinine	  distribution.154,179	  
Moreover,	   higher	   creatinine	   at	   RRT	   initiation	   has	   been	   associated	   with	   better	  
outcome,15,37,179	   possibly	   related	   to	   better	   nutritional	   status	   or	   underlying	   chronic	  
kidney	  disease	  and,	  thus,	  different	  course	  of	  illness.15	  	  	  
	  Several	   retrospective	   studies	   in	   cardiac	   surgical	   ICUs	   have	   compared	   decreased	  
urine	   output	   not	   responding	   to	   fluid	   and/or	   diuretic	   treatment	   as	   a	   trigger	   for	   early	  
RRT	  initiation.61,71	  109,156	  Compared	  to	  late	  initiation	  defined	  either	  as	  marked	  increase	  
in	   creatinine71,	   61,156	   or	   delaying	   RRT	   initiation	   48h	   after	   diagnosing	   AKI,109	   patients	  
with	  early	  RRT	  survived	  better.	  A	  strong	  association	  between	  decreased	  urine	  output	  
and	  mortality	  has	  also	  been	  found.16	  	  
Fluid	   accumulation	   and	   edema	   are	   common	   indications	   for	   RRT.16,204,230	   Among	  
patients	  with	  acute	  lung	  injury,	  a	  conservative	  fluid	  management	  strategy	  compared	  to	  
a	   liberal	   strategy	   lead	   to	   better	   survival	   without	   increasing	   the	   need	   for	   RRT.248	   A	  
further	  analysis	  of	  patients	  with	  AKI	  from	  the	  same	  study	  showed	  that	  after	  adjusting	  
for	  multiple	  covariates,	  more	  positive	  fluid	  balance	  after	  AKI	  diagnosis	  was	  associated	  
with	  mortality	  although	  crude	  mortality	  did	  not	  differ	  significantly.92	  Similarly,	  a	  small	  
retrospective	   study	   in	   patients	   with	   septic	   shock	   found	   that	   patients	   achieving	   a	  
negative	  balance	  during	  their	  first	  three	  days	  in	  the	  ICU	  survived	  better.3	  In	  fact,	  fluid	  
balance	   as	   biomarker	   of	   critical	   illness	   has	   been	   proposed.9	   Several	   studies	   among	  
critically	  ill	  children	  with	  CRRT	  have	  reported	  an	  association	  between	  a	  higher	  degree	  
of	   fluid	   accumulation	   and	   worse	   outcome.89,97,227	   Non-­‐survivors	   in	   a	   cohort	   study	  
including	   AKI	   patients	  with	   and	  without	   RRT	   had	   a	   significantly	  more	   positive	   daily	  
fluid	   balance	   compared	   to	   survivors.189	   An	   association	   between	   mean	   daily	   fluid	  
balance	  after	  RRT	  initiation	  and	  mortality	  has	  also	  been	  found.205	  Among	  RRT	  patients,	  
after	   adjusting	   for	   dialysis	   modality	   and	   APACHE	   III	   score,	   patients	   with	   fluid	  
accumulation	  >10%	  of	  baseline	  weight	  at	  RRT	  initiation	  had	  an	  OR	  of	  2.07	  for	  death.25	  
Another	  study	  found	  an	  association	  between	  degree	  of	  fluid	  accumulation	  from	  the	  24h	  
preceding	   RRT	   initiation	   and	   mortality.16	   Thus,	   initiating	   RRT	   before	   severe	   fluid	  
accumulation	  may	  improve	  outcome.	  	  
2.7.2 MODALITY 
Whether	  critically	  ill	  patients	  with	  AKI	  should	  receive	  intermittent	  or	  continuous	  RRT	  
has	  been	  addressed	  in	  many	  RCTs.	  A	  French	  multicenter	  RCT	  found	  no	  difference	  in	  the	  
60-­‐day	   survival	   or	   occurrence	   of	   hypotension	   in	   patients	   with	   acute	   renal	   failure	  
(creatinine	   over	   310	   μmol/L	   or	   urea	   >36	   mmol/L)	   and	   multiple	   organ	   dysfunction	  
receiving	   CVVHDF	   compared	   to	   patients	   with	   IHD.241	  When	   post-­‐dilution	   CVVH	  was	  
compared	  to	  IHD	  in	  patients	  stratified	  according	  to	  the	  severity	  of	  illness,	  no	  difference	  
in	   survival	   between	   the	   groups	   was	   found,	   although	   patients	   with	   coagulation	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disturbances	   and	   severe	   hemodynamic	   instability	   were	   partly	   excluded.145	   When	  
CVVHDF	  was	  also	  compared	   to	   IHD	   in	  a	   trial	  where	  significant	  differences	   in	  disease	  
severity	   between	   the	   treatment	   groups	   existed,	   again,	   no	   difference	  was	   found	   after	  
adjustments	   for	   disease	   severity.161	   Similar	   results	   have	   also	   been	   reported	   from	  
single-­‐center	  RCTs	  comparing	  CRRT	  and	   IHD7,176,232	   and	  CRRT	  compared	   to	  extended	  
daily	  dialysis.125	  One	  RCT	  did	  report	  a	  significant	  decrease	  in	  mean	  arterial	  pressure	  in	  
patients	   during	   IHD,	   which	   however,	   did	   not	   affect	   survival.7	   The	   hemodynamic	  
tolerability	   of	   sustained	   low-­‐efficiency	   dialysis	   has	   been	   found	   to	   be	   comparable	   to	  
CRRT	  in	  an	  observational	  cohort	  study.79	  A	  meta-­‐analysis8	  and	  a	  systematic	  review188	  
found	   no	   differences	   in	   survival	   between	   CRRT	   and	   IHD	   patients.	   A	   Cochrane	  meta-­‐
analysis	  concluded	   that	  no	  modality	  was	  preferred	  over	  another	   in	  hemodynamically	  
stable	  patients,	  but	  CRRT	  was	  associated	  with	  greater	  hemodynamic	   stability,201	   and,	  
thus	  CRRT	  is	  suggested	  to	  be	  preferred	  among	  hemodynamically	  unstable	  patients.120	  
2.7.3 DOSE 
The	   optimal	   RRT	   dose	   for	   critically	   ill	   AKI	   patients	   has	   been	   intensively	   researched	  
during	  the	  last	  decade;	  however,	  only	  one	  study	  has	  focused	  on	  the	  optimal	  intensity	  of	  
IHD	  comparing	  daily	  IHD	  sessions	  to	  alternate	  day	  IHD.215	  In	  this	  study,	  patients	  in	  the	  
daily	   IHD	  group	  were	   found	   to	  have	   lower	  mortality	   and	  better	   control	  of	  uremia:215	  
the	  urea	  Kt/V	  was	  1.2	  per	  IHD	  session.215	  	  
Ronco	   et	   al.208	   conducted	   the	   first	   RCT	   comparing	   different	   dosing	   strategies	   in	  
CRRT.	  Patients	  were	  randomized	  to	  receive	  postdilution	  CVVH	  either	  20	  mL/kg/h,	  35	  
mL/kg/h	   or	   45	  mL/kg/h.	   Patients	   receiving	   a	   dose	   of	   20	  mL/kg/h	   had	   significantly	  
higher	   mortality	   compared	   to	   the	   two	   groups	   with	   a	   higher	   dose.	   No	   difference	   in	  
mortality	  was	   found	   between	   the	   two	   groups	  with	   the	   higher	   dose,	   and	   a	   dose	   of	   at	  
least	  35	  mL/kg/h	  was	  recommended.	  Several	  smaller	  RCTs	  have	  also	  compared	  CVVH	  
or	  CVVHDF	  with	  a	  lower	  dose	  of	  19-­‐25	  mL/kg/h	  to	  a	  more	  intensive	  dose	  ranging	  from	  
35	  to	  48	  mL/kg/h.26,211,229	  Two	  of	  these	  studies26,229	  found	  no	  survival	  benefit	  of	  higher	  
dose	  in	  terms	  of	  short-­‐term	  survival,	  whereas	  patients	  with	  higher	  dose	  in	  the	  study	  by	  
Saudan	   et	   al.211	   had	   a	   lower	   90-­‐day	  mortality	   rate	   compared	   to	   patients	  with	   a	   less-­‐
intensive	  dose.	  	  
A	   large	   multicenter	   RCT187	   (ATN	   study)	   with	   1124	   patients	   compared	   intensive	  
RRT	  (IHD	  or	  sustained	  low-­‐efficiency	  dialysis	  6	  times	  a	  week	  or	  CVVHDF	  35	  mL/kg/h)	  
to	  less-­‐intensive	  treatment	  (IHD	  or	  sustained	  low-­‐efficiency	  dialysis	  3	  times	  a	  week	  or	  
CVVHDF	   20	  mL/kg/h)	   in	   terms	   of	   60-­‐day	   survival.	   Kt/V	   for	   intermittent	   modalities	  
was	  1.3	  per	  session.	  No	  difference	  in	  survival	  was	  detected	  between	  the	  intensive	  and	  
less-­‐intensive	  treatment.	  Notably,	  the	  median	  daily	  duration	  of	  CRRT	  was	  21	  hours	  for	  
both	  groups,	  and	  89%	  of	  prescribed	  CRRT	  dose	  in	  the	  intensive	  group,	  and	  95%	  in	  the	  
less-­‐intensive	  group,	  was	  delivered.	  	  
In	   the	  RENAL	   study,204	   1508	  patients	  were	   randomized	   to	   receive	   either	   a	   lower	  
dose	   of	   25	   mL/kg/h	   or	   a	   higher	   dose	   of	   40	   mL/kg/h	   of	   postdilution	   CVVHDF.	   No	  
difference	   in	   the	  90-­‐day	  mortality	  between	   these	   two	   strategies	  was	   found,	   although	  
the	   mortality	   rate	   was	   lower	   than	   in	   the	   ATN	   study187	   despite	   comparable	   disease	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severity:	  44.7%	  in	  RENAL	  vs.	  51.5-­‐53.7%	  in	  ATN.	  The	  delivered	  dose	  was	  84%	  of	  the	  
prescribed	  dose	  in	  the	  higher	  intensity	  group	  and	  88%	  in	  the	  lower-­‐intensity	  group.204	  
The	   results	   of	   IVOIRE	   (high	   volume	   in	   intensive	   care)	   study104	   comparing	   CVVH	   35	  
mL/kg/h	  to	  70	  mL/kg/h	  in	  septic	  patients	  have	  not	  yet	  been	  published	  completely,	  but	  
the	  overall	  90-­‐day	  mortality	  was	  51%.	  
Several	  meta-­‐analyses	   regarding	   the	   intensity	   of	  RRT	  have	   concluded	   that	   higher	  
intensity	   does	   not	   improve	   survival	   and	   a	   CRRT	   dose	   of	   20-­‐25	   mL/kg/h	   is	  
sufficient,114,172,247	  which	  is	  also	  the	  recommendation	  of	  KDIGO.120	  The	  delivered	  CRRT	  
dose	   measured	   as	   spent	   effluent	   is	   clearly	   less	   than	   the	   prescribed	   dose.187,236,237	  	  
Subsequently,	  to	  ensure	  that	  delivered	  dose	  reaches	  20-­‐25	  mL/kg/h,	  prescription	  of	  a	  
higher	   dose,	   approximately	   30	   mL/kg/h,	   has	   been	   recommended.24,155,120	   Moreover,	  
setting	  individualized	  targets	  for	  fluid	  balance,	  electrolyte	  and	  acid-­‐base	  homeostasis,	  
and	   adjusting	   the	   RRT	   to	   achieve	   these	   targets	   is	   suggested.120,238	   The	   targeted	   dose	  
should	   be	   prescribed,	   and	   the	   actual	   delivered	   dose	   assessed	   regularly,120,155	   which,	  
however,	  is	  not	  the	  current	  practice.183	  Regarding	  IRRT,	  delivering	  a	  Kt/V	  of	  3.9/week	  
is	  recommended.120	  	  
2.7.4 CASE VOLUME 
Association	   with	   high	   case	   volume	   and	   improved	   outcome	   has	   been	   documented	   in	  
several	   fields	   of	   surgery,21,95	   as	   well	   as	   in	   percutaneous	   coronary	   interventions.96,159	  
Depending	   on	   the	   type	   of	   the	   procedure,	   factors	   related	   both	   to	   the	   hospital’s	   case	  
volume	   and	   the	   operating	   physician’s	   case	   volume	   play	   a	   role.22,94	   For	   example,	   in	  
carotid	   endarterectomy,	   the	   case	   volume	   of	   the	   surgeon	   accounted	   for	   the	   volume	  
effect	  more,	  but	  in	  lung	  cancer	  surgery	  that	  frequently	  involves	  complications,	  hospital	  
facilities	   such	   as	   intensive	   care,	   pain	   management,	   and	   nursing	   care	   had	   a	   greater	  
role.22	  Deaths	  could	  potentially	  be	  avoided	   if	   treatment	  of	   certain	  conditions,	   such	  as	  
elective	   abdominal	   aneurysm	   repair	   or	   pancreatic	   and	   esophageal	   cancer	   surgery,	  
would	  be	  concentrated	  to	  high-­‐volume	  centers.68	  	  
Medical	   ICU	   patients	   with	   higher	   disease	   severity	   and	   gastrointestinal	   diagnoses	  
had	   lower	   adjusted	  mortality	   rate	   in	  high-­‐volume	   ICUs,	  whereas	  no	  volume-­‐outcome	  
association	  was	  observed	  among	  patients	  with	  respiratory	  or	  neurological	  diagnoses.69	  
Among	   general	   ICU	   patients,	   no	   volume-­‐outcome	   association	  was	   seen	   in	   the	  whole	  
population,	   although	   an	   association	  with	   better	   outcome	  was	   noted	   in	   ICUs	   treating	  
high	   volumes	   of	   high-­‐risk	   patients	   after	   adjusting	   for	   patient	   risk	   factors	   and	   ICU	  
characteristics.87	  Regarding	   ICU	  patients	  with	   severe	   sepsis,192	  with	   septic	   shock	   and	  
malignancy,257	  and	  non-­‐surgical	  patients	  needing	  mechanical	  ventilation,116	   treatment	  
in	  high	  volume	   ICUs	  has	  been	  associated	  with	  better	  outcome.	  Potential	  explanations	  
for	   the	   positive	   volume-­‐outcome	   effect	   seen	   in	   these	   subgroups	   of	   ICU	   patients	   can	  
include:	  better	  experience	  gained	   in	   treating	  high	  volumes	  of	   these	  patients,	  possibly	  
better	   adopted	   treatment	   protocols	   in	   high	   volume	   ICUs,	   and	   organizational	   factors	  
related	   to	   high	   ICUs	   such	   as	   multidisciplinary	   teams.115	   In	   contrast,	   among	   surgical	  
patients171	  and	  general	  ICU	  patients168	  on	  mechanical	  ventilation,	  no	  volume	  outcome-­‐
effect	  could	  be	  demonstrated.	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Only	   one	   previous	   study	   has	   investigated	   the	   volume-­‐outcome	   effect	   in	   patients	  
treated	  with	  RRT.174	  Nguyen	  et	  al.174	  studied	  9	  449	  French	  and	  3	  498	  U.S.	  non-­‐surgical	  
patients	  retrospectively	  during	  a	  ten-­‐year	  period.	  The	  participating	  ICUs	  were	  divided	  
into	  quartiles	  according	  to	  the	  annual	  case	  volume	  of	  RRT	  treated	  patients,	  which	  was	  
one	   to	   nine	   patients	   in	   the	   smallest	   quartile	   in	   the	   U.S.	   cohort	   and	   59	   to	   129	   in	   the	  
largest	   quartile	   in	   France.	   Notably,	   in	   the	   ICU	   quartiles,	   the	   proportion	   of	   patients	  
treated	   with	   CRRT	   was	   only	   14%	   to	   56%,	   mainly	   under	   30%.	   After	   adjusting	   for	  
patient	   characteristics,	   hospital	   and	   ICU	   characteristics,	   no	   volume-­‐outcome	   effect	  
could	  be	  demonstrated.	  Thus,	   the	  potential	   effect	   of	   high	  volume	  on	  outcome	  among	  
ICU	  patients	  remains	  inadequately	  answered.	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3. AIMS OF THE STUDY 
The	  main	  aims	  of	  this	  study	  were	  to	  evaluate	  the	  incidence	  of	  RRT	  for	  AKI	   in	  Finland	  
and	   the	   outcome	   and	   factors	   associated	  with	   outcome	   in	   patients	   receiving	   RRT	   for	  
AKI.	  Specific	  objectives	  were:	  
 
1. To	   systematically	   review	   the	   quality	   of	   published	   reports	   regarding	   drug	  
pharmacokinetics	   during	   CRRT	   and	   evaluate	   the	   used	   CRRT	   dose	   in	   these	  
studies	  (I)	  
	  
2. To	   evaluate	   the	   population-­‐based	   incidence	   of	   RRT	   treatment	   for	   AKI	   in	  
Finland	  (II,	  IV)	  
	  
3. To	  describe	  the	  RRT	  treatment	  given	  in	  Finnish	  ICUs	  (IV)	  
	  
4. To	   investigate	   the	   short-­‐term	   (II,	   IV)	   and	   long-­‐term	   (II,	   IV)	  mortality	   of	   RRT	  
patients	   treated	   in	   Finnish	   ICUs,	   and	   factors	   associated	   with	   mortality,	  
specifically	  	  
a. ICU	  size	  and	  annual	  case	  volume	  of	  RRT	  (III)	  




4. MATERIALS AND METHODS  
4.1 MATERIALS 
A	   summary	   of	   the	   study	   characteristics	   is	   presented	   in	   Table	   4.	   Study	   I	   was	   a	  
systematic	  review	  including	  49	  original	  publications	  reporting	  drug	  pharmacokinetics	  
during	  CRRT	  (Figure	  2a).	  Studies	  II-­‐IV	  included	  altogether	  25	  200	  patients	  (Figure	  2b).	  
For	  studies	  II-­‐III,	  data	  of	  all	  admissions	  in	  the	  24	  member	  ICUs	  of	  the	  Finnish	  Intensive	  
Care	  Consortium	  during	  the	  study	  period	   from	  1	   January	  2007	  to	  31	  December	  2008	  
were	  obtained.	  The	  1558	  patients	  in	  study	  III	  comprised	  a	  subcohort	  of	  study	  II.	  Study	  
IV	  was	  a	  part	  of	  the	  FINNAKI	  study	  conducted	  in	  17	  ICUs	  between	  1	  September	  2011	  
and	  1	  February	  2012.	  Patient	  characteristics	  in	  studies	  II-­‐IV	  are	  presented	  in	  Table	  5.	  	  	  
The	   ethics	   committee	   of	   the	   Department	   of	   Surgery,	   Hospital	   District	   of	   Helsinki	  
and	   Uusimaa	   waived	   the	   need	   for	   consent	   in	   studies	   II-­‐III.	   In	   study	   IV,	   the	   study	  
protocol	   and	   the	   use	   of	   deferred	   consent	   with	   a	   signed	   informed	   consent	   from	   the	  
patient	  or	  proxy	  were	  approved.	  The	  Finnish	  National	  Institute	  of	  Health	  gave	  approval	  
for	  the	  collection	  of	  data	  from	  medical	  records	  of	  deceased	  patients	  if	  consent	  could	  not	  




Table 4. Study characteristics. 
 
 
Study # Study design Patient # Main objectives 
I Systematic review  Quality of pharmacokinetic studies and 
the adequacy of the used CRRT dose 
II Retrospective cohort 24 904 Incidence of RRT for AKI, mortality and 
HRQOL of RRT-treated patients 
III Retrospective cohort 1558 Association of ICU size and annual case 




296 90-day mortality and factors associated 
with it, especially fluid overload 
 
AKI; acute kidney injury, CRRT; continuous renal replacement therapy, HRQOL; health-











































Table 5. Patient characteristics. 
 









Age (years) 62 [50-73] 63 [52-72] 63 [52-72] 64 [55-73] 
























SAPS II score 33 [23-46] 48 [37-62] 50 [39-63] 51 [40-65] 
SOFA score (first ICU 
treatment day) 
6 [3-8] 10 [7-13] 10 [7-13] 10 [8-13] 
























ICU length of stay 
(days) 
1.5 [0.9-3.2] 5.2 [1.9-10.8] 5.3 [1.9-10.8] 5.5 [2.2-
10.9] 
Hospital length of stay 
(days) 
9 [5-16] 16 [8-29] 16 [8-29] 14.5 [6.0-
27.3] 
Continuous data expressed as median [IQR] and categorical data as number/total number 
(%). 
ICU; intensive care unit; IQR; interquartile range, non-RRT; patients without renal 
replacement therapy, RRT; renal replacement therapy, SAPS; Simplified Acute Physiology 
Score, SOFA; Sequental Organ Failure Assessment, TISS; Therapeutic Intervention Scoring 
System 
a On the first 24h of ICU treatment 
4.2 STUDY DESIGNS 
Study	  I	  
For	  this	  systematic	  review,	  a	  search	  was	  performed	  in	  Medline,	  PubMed,	  EMBASE,	  and	  
Cochrane	  databases	  considering	  all	  citations	  entered	  in	  the	  databases	  by	  31	  December	  
2009.	  The	  search	  terms	  are	  presented	  in	  Table	  6.	  Two	  independent	  reviewers	  screened	  
all	  citations	  for	  relevance	  according	  to	  the	  inclusion	  criteria	  (Table	  6).	  To	  supplement	  
the	   database	   search,	   the	   bibliographies	   of	   the	   relevant	   review	   articles	   found	   in	   the	  
search	   were	   also	   screened.	   Finally,	   49	   articles	   fulfilled	   the	   inclusion	   criteria	   (Figure	  
2a).	   These	   articles	   reported	   from	   64	   separate	   pharmacokinetic	   studies.	   The	   general	  
quality	  of	   the	   included	  studies	  was	  assessed	  with	   the	  Downs	  and	  Black	  quality	   score	  
index.66	   To	   evaluate	   the	   adequacy	   of	   reporting	  CRRT-­‐related	  data,	   the	  Acute	  Dialysis	  
Quality	   Initiative	   minimum	   reporting	   criteria	   for	   CRRT	   studies	   were	   used.86,124	   The	  





Table 6. Literature search strategy and inclusion criteria for study I.  
	  
Search strategy 
1. “acute kidney injury” OR “acute renal insufficiency” 
2. “renal replacement therapy” 
3. “pharmacokinetics” 
4. “critical illness” OR “intensive care” OR “critical care” 
Terms 1 to 4 were combined with Boolean operator AND  
 
Inclusion criteria 
1. reported original data from a primary publication reported in English 
2. reported data from adult human subjects 
3. included critically ill subjects receiving continuous venovenous RRT for AKI 
4. focused on drug pharmacokinetics 
5. reported parameters needed for calculation of continuous RRT dose 
 
AKI; acute kidney injury, RRT; renal replacement therapy 
Study	  II	  
In	  this	  retrospective	  cohort	  study,	  patients	  who	  received	  RRT	  for	  AKI	  were	   identified	  
and	  compared	  to	  patients	  without	  RRT	  in	  terms	  of	  mortality	  and	  HRQOL.	  Altogether	  	  
30	  380	  admissions	  to	  Finnish	  Intensive	  Care	  Consortium	  member	  ICUs	  were	  screened.	  
Readmissions,	   patients	   with	   end-­‐stage	   renal	   disease,	   patients	   <15	   years	   old,	   and	  
patients	   who	   were	   admitted	   because	   of	   drug	   or	   alcohol	   intoxication	   were	   excluded	  
(Figure	  2b).	  For	  incidence	  calculations,	  data	  on	  the	  Finnish	  population	  over	  the	  age	  of	  
15	  on	  31	  December	  2007	  were	  obtained	  from	  Statistics	  Finland.	  	  
 
Study	  III	  
In	   this	   retrospective	   cohort	   study,	   the	   crude	   and	   adjusted	   mortality	   of	   RRT-­‐treated	  
patients	  were	   compared	   in;	   1)	   small	   vs.	   large	   ICUs	   and,	  2)	   in	   low,	  medium,	   and	  high	  
volume	   ICUs	   classified	   according	   to	   the	   annual	   case	   volume	   of	   RRT-­‐treated	   patients.	  
From	   the	   2413	   patients	   with	   RRT	   in	   study	   II,	   cardiac	   surgical	   and	   neurosurgical	  
patients,	   patients	   without	   data	   on	   outcome	   or	   SAPS	   II	   or	   SOFA	   severity	   scores,	   and	  
patients	  under	  18	  years	  of	  age	  were	  further	  excluded	  (Figure	  2b).	  
 
Study	  IV	  
The	  FINNAKI	  study	  was	  a	  prospective,	  observational,	  cohort	  study.	  Factors	  associated	  
with	  90-­‐day	  mortality	  of	  RRT-­‐treated	  patients	  with	  special	  emphasis	  on	  fluid	  balance	  
prior	   to	  RRT	   initiation	  were	   analyzed.	  During	   the	   five-­‐month	   study	  period,	   the	  5853	  
ICU	   admissions	   in	   the	  participating	   ICUs	  were	   screened	   for	   eligibility.	  All	   emergency	  
admissions	  and	  elective	  admissions	  with	  an	  expected	  stay	  over	  24h	  were	   included	   in	  
the	  FINNAKI	  study.	  Patients	  who	  received	  RRT	  for	  AKI	  were	  included	  in	  study	  IV.	  The	  
following	   patient	   groups	   were	   excluded;	   1)	   patients	   with	   ESRD	   on	   maintenance	  
dialysis,	  2)	  patients	  who	  had	  already	  participated	   in	   the	  study	  and	  who	  had	  received	  
RRT	  already	  on	  that	  previous	  admission,	  3)	  patients	  without	  consent,	  4)	  patients	  who	  
were	   not	   permanently	   living	   in	   Finland,	   5)	   patients	   on	   intermediate	   care	   and,	   6)	  
patients	  who	  received	  RRT	  for	  non-­‐renal	  indications	  (Figure	  2b).	  
	  
 43	  
4.3 DATA COLLECTION 
In	  study	  I,	  data	  on	  the	  studied	  drug	  and	  its	  dosing,	  patient	  demographics,	  details	  of	  the	  
given	   RRT	   treatment,	   and	   patient	   weight	   to	   calculate	   the	   CRRT	   dose	   adjusted	   for	  
weight	  were	   collected.	   Pharmacokinetic	   parameters	   (Vd,	   T1/2,	   area	   under	   the	   curve	  
(AUC)),	   total	   clearance,	   CRRT	   clearance,	   renal	   clearance,	   and	   sieving/saturation	  
coefficient)	  and	  recommendations	  given	  for	  drug	  dosing	  were	  recorded.	  	  
The	   clinical	   data	   used	   in	   studies	   II-­‐IV	  were	   retrieved	   from	   the	   Finnish	   Intensive	  
Care	   Consortium	   database.	   The	   database	   was	   originally	   based	   for	   benchmarking	  
purposes.	   Data	   on	   patient	   APACHE	   III	   admission	   diagnosis,127	   International	  
Classifications	  of	  Diseases,	  10th	  revision	  (ICD-­‐10)	  diagnosis,	  demographic	  data,	  as	  well	  
as	  physiologic	  and	   laboratory	  data	  needed	  for	  calculating	  the	  SAPS	  II,136	  SOFA,239	  and	  
APACHE	   II126	   severity	   scores	   are	   routinely	   collected.	   Additionally,	   data	   for	   the	  
Therapeutic	   Intervention	   Scoring	   System	   (TISS)122	   are	   recorded.	   The	   data	   are	  
transferred	   directly	   from	   the	   ICU	   clinical	   information	   management	   system	   to	   the	  
database,	   after	   being	   validated	   by	   trained	   personnel	   and	   filtered	   for	   outliers.	   For	  
studies	  II	  and	  III,	  the	  routine	  data	  including	  the	  demographic	  data,	  diagnoses,	  as	  well	  as	  
daily	  creatinine	  values	  were	  obtained.	  The	  SAPS	  II	  and	  SOFA	  scores,	  in	  addition	  to	  the	  
physiologic	   data	   regarding	   the	   first	   day	   of	   ICU	   treatment,	   were	   used.	   Patients’	   vital	  
status	  at	  hospital	  discharge	  and	  at	  six	  months,	  were	  obtained	  from	  the	  database.	  
For	  study	  IV,	  the	  routine	  data	  collection	  set	  was	  expanded	  to	  include	  all	  physiologic	  
and	   laboratory	   data	   recorded	   in	   the	   clinical	   information	   system.	   Additionally,	  
supplementary	  data	  on	  patients’	  chronic	   illnesses,	  medication,	  and	  treatment	  prior	  to	  
ICU	   admission	   were	   collected	   with	   case	   report	   forms.	   Data	   on	   daily	   fluid	   balance,	  
characteristics	   of	   the	   given	  RRT,	   and	   patients’	   sepsis	   status	   on	   days	   one	   to	   five,	   and	  
data	  on	  RRT	  thereafter	  twice	  a	  week	  were	  recorded.	  Data	  on	  patients	  RRT	  need	  at	  90	  
days	   were	   collected.	   Data	   on	   patients’	   vital	   status	   at	   90	   days	   from	   the	   Finnish	  
Population	  Register	  Centre	  were	  obtained.	  	  
4.4 DEFINITIONS 
Organ	  dysfunction	  (II-­‐IV)	  
Organ	  dysfunction	  was	  defined	  as	  an	  organ	  specific	  SOFA	  score	  3	  or	  4.240	  	  
Sepsis	  (II-­‐IV)	  
In	  studies	   II	  and	   III,	   the	  presence	  of	  sepsis	  was	  retrospectively	  assessed	  according	   to	  
the	  American	  College	  of	  Chest	  Physicians	  /	  Society	  of	  Critical	  Care	  Medicine	  criteria.23	  
Data	   on	   presence	   of	   infection	   were	   based	   on	   patients’	   APACHE	   III	   and	   ICD-­‐10	  
diagnosis.	  Presence	  of	  systemic	  inflammatory	  response	  syndrome	  was	  screened	  using	  
physiologic	  data	  from	  the	  first	  24	  hours	  of	  ICU	  treatment	  and	  organ	  failures	  using	  the	  
first	   day’s	   SOFA	   score.	   In	   study	   IV,	   the	   presence	   of	   severe	   sepsis	  was	   assessed	   daily	  
from	  admission	  to	  fifth	  ICU	  treatment	  day	  on	  the	  basis	  of	  the	  American	  College	  of	  Chest	  




Acute	  kidney	  injury	  (II)	  
The	  presence	  of	  AKI	  was	  retrospectively	  screened	  according	  to	  the	  creatinine	  criteria	  
of	   the	   RIFLE	   classification	   (Table	   1).19	   The	   lowest	   value	   of	   the	   following:	   lowest	  
recorded	   creatinine	   value	   during	   the	   entire	   ICU	   stay	   or	   the	   calculated	   baseline	  
creatinine,	   was	   used	   as	   baseline	   creatinine.	   The	   baseline	   creatinine	   was	   calculated	  
using	  the	  MDRD	  equation	  assuming	  a	  GFR	  of	  75	  mL/min/1.73m2	  as	  recommended	  by	  
Acute	  Dialysis	  Quality	  Initiative.19	  	  
ICU	  size	  and	  annual	  case	  volume	  (III)	  
A	  previous	   Finnish	   Intensive	   Care	   Consortium	   classification	  was	   used	   to	   divide	   ICUs	  
into	   small	   (n=7)	   and	   large	   (n=16).202	   Small	   ICUs	   had	   a	   referral	   area	   under	   120	   000	  
inhabitants	   and/or	   fewer	   than	   six	   beds.	   The	   annual	   case	   volume	   of	   RRT-­‐treated	  AKI	  
patients	  in	  each	  ICU	  (the	  mean	  case	  volume	  of	  the	  two	  years)	  was	  calculated.	  The	  ICUs	  
were	  divided	  into	  volume	  tertiles	  according	  to	  the	  mean	  annual	  case	  volume;	  low	  (n=9,	  
two	   ICUs	   had	   equal	   annual	   case	   volume	   on	   the	   border	   of	   low	   and	   medium	   tertile),	  
medium	  (n=7),	  and	  high	  (n=7).	  	  
Fluid	  overload	  (IV)	  
The	  cumulative	  fluid	  balance	  from	  ICU	  admission	  to	  RRT	  initiation	  (including	  the	  day	  
of	  RRT	  initiation)	  was	  calculated.	  To	  define	  the	  degree	  of	  fluid	  overload,	  the	  cumulative	  
balance	   in	   liters	   was	   divided	   by	   patient’s	   baseline	   weight	   and	   multiplied	   by	   100%.	  
Fluid	   accumulation	   of	   10%	   was	   used	   as	   a	   cut-­‐off	   to	   define	   presence	   of	   fluid	  
overload.25,27	  	  	  
4.5 OUTCOME MEASURES 
Mortality	  (II-­‐IV)	  
Data	   on	   patients’	   vital	   status	   at	   hospital	   discharge	   and	   at	   six	   months	   after	   ICU	  
admission	  were	  obtained	   from	  the	  Finnish	   Intensive	  Care	  Consortium	  database.	  Data	  
on	   patients’	   time	   of	   death	   are	   registered	   in	   the	   database	   of	   the	   Finnish	   Population	  
Register	  Centre	  and	  the	  social	  security	  codes	  of	  the	  patients	   in	  study	  IV	  were	  used	  to	  
obtain	  these	  data.	  	  
Standardized	  mortality	  ratio	  (SMR)	  (II-­‐IV)	  
The	   SAPS	   II	   –based	   SMR	   was	   calculated	   using	   the	   expected	   probability	   of	   death	  
calculated	   from	  the	  original	  SAPS	  II	  equation.136	  The	  sum	  of	  observed	  deaths	  (O)	   in	  a	  
cohort	  was	   divided	   by	   the	   sum	   of	   the	   expected	   deaths	   (E),	   which	   is	   the	   SMR	   of	   the	  
population	  (O/E	  –ratio).	  A	  SMR	  below	  one	  means	  that	  the	  observed	  mortality	  is	  lower	  
than	  what	  could	  be	  expected	  using	  the	  prediction	  model.	  Adjusted	  mortality	  rates	  were	  
calculated	  for	  patient	  sub-­‐cohorts	  in	  study	  III	  by	  multiplying	  the	  SMR	  in	  the	  sub-­‐cohort	  
with	  the	  overall	  mortality	  of	  the	  cohort.	  	  
Renal	  recovery	  at	  90	  days	  (IV)	  




Health-­‐related	  quality	  of	  life	  (HRQOL)	  (II)	  
The	  HRQOL	  of	  all	  patients	  admitted	  to	  the	  ICU	  were	  assessed	  at	  baseline	  (referring	  to	  
situation	  prior	  to	  critical	  illness)	  and	  at	  six	  months	  after	  ICU	  admission	  with	  the	  EQ-­‐5D	  
instrument30	   as	   a	   part	   of	   the	   routine	   data	   collection	   of	   the	   Finnish	   Intensive	   Care	  
Consortium.	  Either	  the	  patient	  him-­‐/herself	  or	  a	  proxy	  answered	  the	  questions.	  At	  six	  
months,	  the	  questionnaire	  was	  either	  performed	  by	  phone	  interview	  or	  mailed	  to	  the	  
home.	  The	  data	  provider	  (patient/proxy)	  was	  recorded.	  	  
The	   EQ-­‐5D	   questionnaire30	   (Table	   7)	   consists	   of	   five	   dimensions:	   1)	  mobility,	   2)	  
self-­‐care,	   3)	   usual	   activities	   (such	   as	   work,	   family	   or	   leisure	   activities),	   4)	  
pain/discomfort	   and,	   5)	   anxiety/depression.	   Each	   dimension	   is	   scored	   from	   1	   to	   3.	  
Data	   on	   population-­‐based	   reference	   values	   are	   used	   to	   calculate	   the	   index	   score	  
(maximum	  1).	  Additionally,	  the	  patient’s	  perception	  of	  his/hers	  current	  health	  state	  is	  
assessed	   using	   the	   visual-­‐analogue	   scale	   (VAS)	   from	   0	   to	   100	   (100	   representing	   the	  
best	  possible	  health	  state).30	  
 
Table 7. The EQ-5D health questionnaire by Brooks et al.30 
 
By placing a tick in one box in each group, please indicate which statements best describe 
your health today. 
 
Mobility  
I have no problems in walking about □ 
I have some problems in walking about □ 
I am confined to bed □ 
  
Self-Care  
I have no problems with self -care □ 
I have some problems washing or dressing myself □ 
I am unable to wash or dress myself □ 
  
Usual Activities (e.g. work, study, housework, family or 
leisure activities) 
 
I have no problems with performing my usual activities □ 
I have some problems with performing my usual activities □ 
I am unable to perform my usual activities □ 
  
Pain/Discomfort  
I have no pain or discomfort □ 
I have moderate pain or discomfort □ 
I have extreme pain or discomfort □ 
  
Anxiety/Depression  
I am not anxious or depressed □ 
I am moderately anxious or depressed □ 




4.6 STATISTICAL ANALYSES 
Data	  and	  statistical	  tests	  
The	   normality	   of	   continuous	   variables	   was	   examined	  with	   the	   Kolmogorov-­‐Smirnov	  
test,	  and	  as	  variables	  were	  not	  normally	  distributed,	  continuous	  data	  were	  reported	  as	  
medians	   with	   interquartile	   range	   (IQR,	   25th	   -­‐75th	   percentiles)	   and	   nominal	   data	   as	  
count	  and	  percentage.	  A	   two-­‐sided	  P-­‐value	  <0.05	  was	  considered	   to	  be	  significant.	   In	  
logistic	  regression,	  a	  P-­‐value	  <0.05	  in	  studies	  II-­‐III,	  and	  a	  more	  strict	  P-­‐value	  of	  <0.01	  in	  
study	  IV,	  was	  considered	  to	  be	  significant.	  	  
Chi-­‐square	   test	   or	   Fisher’s	   exact	   test	   was	   used,	   as	   appropriate,	   to	   compare	  
categorical	   variables.	   Mann-­‐Whitney	   U-­‐test	   was	   used	   to	   compare	   two,	   and	   Kruskal-­‐
Wallis	   to	   test	   three,	   continuous	   variables.	   Wilcoxon	   signed	   rank	   test	   was	   used	   to	  
compare	   repeatedly	  measured	   data	   of	  HRQOL	   (II).	   Kaplan-­‐Meyer	   survival	   curves	   for	  
patients	  with	  and	  without	  fluid	  overload	  were	  constructed	  and	  compared	  with	  the	  log-­‐
rank	  test	  (IV).	  	  
Logistic	  regression	  (II-­‐IV)	  
Binomial	   logistic	   regression	   was	   used	   to	   study	   factors	   associated	   with	   hospital	  
mortality	  (II,	  III)	  and	  90-­‐day	  mortality	  (IV).	  A	  backwards	  elimination	  approach	  with	  a	  
significance	   level	   of	   <0.05	   for	   entry	   and	   >0.10	   for	   stepwise	   removal	   was	   used.	   The	  
goodness-­‐of-­‐fit	  of	  the	  model	  (model	  calibration)	  was	  assessed	  with	  Hosmer-­‐Lemeshow	  
statistics.	  To	  measure	  discrimination	  of	  the	  model	  (the	  ability	  of	  the	  model	  to	  predict	  
the	   outcome),	   the	   correct	   classification	   rate	   was	   calculated.	   Additionally,	   the	   area	  
under	  the	  receiver-­‐operator	  characteristic	  curve	  was	  calculated	  for	  the	  final	  model	   in	  
study	  IV	  to	  measure	  discrimination.	  
In	  the	  logistic	  regression	  models,	  odds	  ratios	  (OR)	  are	  routinely	  used	  as	  measures	  
of	   association.	  ORs	   are	  not	   equivalent	   to	   risk	   ratios	   (RR),	   and	   the	  more	   common	   the	  
studied	  outcome	  is,	  the	  more	  ORs	  overestimate	  the	  RR.216	  	  	  
Propensity	  score	  (III)	  
Propensity	   score	   is	   increasingly	   used	   in	   observational	   studies,	   where	   the	   treatment	  
assignment	   cannot	  be	   controlled.83	   It	   is	  used	   to	   control	   for	   confounding	   in	   treatment	  
effect	  caused	  by	  the	  differences	  in	  the	  treatment	  assignment.83	  The	  propensity	  score	  is	  
the	   conditional	   probability	   that	   the	   study	   subject	   receives	   the	   treatment	   in	   question	  
when	  all	  measured	  confounding	  factors	  have	  been	  accounted	  for.29	  A	  propensity	  score	  
model	  to	  adjust	  for	  potential	  differences	  in	  the	  probability	  of	  a	  patient	  to	  receive	  RRT	  
was	   generated	   in	   study	   III.	   Data	   from	   patients	   without	   (n=19	   122)	   and	   with	   RRT	  
(n=1558)	   were	   used.	   Variables	   found	   to	   significantly	   differ	   between	   these	   patient	  
groups	  (age,	  sex,	  medical	  admission,	  elective	  admission,	  presence	  of	  sepsis,	  renal	  and	  
extra-­‐renal	  SOFA	  score	  (on	  day	  1),	  and	  SAPS	  II	  score	  without	  age	  points)	  were	  entered	  
in	  the	  logistic	  regression	  model,	  of	  which	  a	  propensity	  score	  for	  each	  patient	  to	  receive	  




5.1 QUALITY OF PHARMACOKINETIC STUDIES (I) 
The	  literature	  search	  revealed	  95	  relevant	  original	  articles,	  of	  which	  49	  (52%)	  fulfilled	  
the	   inclusion	   criteria.	   Seven	   of	   the	   included	   publications	   were	   case	   reports.	   The	   49	  
publications	  reported	  of	  64	  separate	  studies	  that	  included	  a	  median	  (IQR)	  number	  of	  6	  
(4-­‐7)	  patients.	  The	  median	  (IQR)	  Downs	  and	  Black	  quality	  score	  calculated	  for	  the	  42	  
original	  publications	  was	  15	  (14-­‐16)	  of	  32.	  The	  median	  (IQR)	  total	  number	  of	  reported	  
minimum	   reporting	   criteria	   by	   Acute	   Dialysis	   Quality	   Initiative	   in	   the	   49	   original	  
articles	  was	  7	  (5-­‐8)	  of	  12,	  and	  reported	  operational	  and	  patient	  characteristics	  was	  4	  
(3-­‐5)	  and	  3	  (1-­‐4)	  of	  6.	  When	  studies	  published	  before	  and	  after	  2002	  were	  compared	  in	  
terms	   of	   number	   of	   reported	   Acute	   Dialysis	   Quality	   Initiative	   criteria,	   no	   significant	  
improvement	  was	  found	  (P=0.341).	  
The	  median	  (IQR)	  calculated	  mean	  CRRT	  dose	  in	  the	  64	  separate	  studies	  was	  22.1	  
(14.3-­‐27.6)	  mL/kg/h	   and	   the	   patient	   count–weighted	   (n=367)	   dose	   23.7	   (18.8-­‐27.9)	  
mL/kg/h.	   In	   32	   (50%)	   studies	   the	   calculations	  were	  based	  on	  measured	  ultrafiltrate	  
flow.	   The	   duration	   of	   CRRT	  was	   reported	   in	   18	   (28%)	   of	   the	   studies.	   The	  weighted	  
CRRT	  dose	  was	  significantly	  higher	  in	  studies	  published	  after	  the	  year	  2001	  compared	  
to	  those	  published	  before,	  24.2	  (18.8-­‐27.9)	  vs.	  19.7	  (13.5-­‐25.1)	  mL/kg/h,	  P=0.033.	  	  	  
5.2 INCIDENCE OF RRT FOR AKI (II, IV) 
Between	  1	  January	  2007	  and	  31	  December	  2008,	  1686	  patients	  received	  RRT	  for	  AKI.	  
The	  population-­‐based	  incidence	  of	  RRT	  for	  AKI	  (95%	  CI)	  was	  19.2	  (17.9-­‐20.5)	  per	  	  
100	  000	  per	  year	  among	  ≥	  15	  year-­‐old	  Finnish	  inhabitants	  (reference	  population	  	  
4	  383	  358)	  (II).	  When	  patients	  under	  18	  (n=6)	  were	  excluded,	  the	  incidence	  (95%	  CI)	  
among	   the	   Finnish	   adult	   population	   was	   20.2	   (18.8-­‐21.5)	   per	   100	   000	   per	   year	  
(reference	   population	   4	   182	   978)	   (unpublished	   data).	   From	   1	   September	   2011	   to	   1	  
February	  2012,	  296	  adults	  were	   treated	  with	  RRT	   for	  AKI,	   and	   the	  population-­‐based	  
incidence	   (95%	   CI)	   was	   19.4	   (17.2-­‐21.6)	   per	   100	   000	   adults	   per	   year	   (reference	  
population	   3	   671	   143)	   (IV).	   The	   population-­‐based	   incidences	   in	   studies	   II	   and	   IV,	  
according	  to	  hospital	  districts,	  are	  presented	  in	  Figure	  3.	  The	  ICU-­‐incidence	  (95%	  CI)	  of	  







































































5.3 PATIENT CHARACTERISTICS (II-IV) 
When	   patients	   in	   study	   IV	   and	   RRT	   patients	   in	   study	   II	   were	   compared	   in	   terms	   of	  
patient	  characteristics	  presented	  in	  Table	  5,	  patients	   in	  study	  IV	  had	  more	  frequently	  
surgical	  admission	  (P=0.007),	  higher	  SAPS	  II	  (P=0.009),	  SOFA	  (P=0.033),	  and	  average	  
TISS	  scores	  (P=0.004).	  The	  length	  of	  hospital	  stay	  was	  longer	  in	  study	  II	  (P=0.049).	  No	  
statistically	  significant	  differences	   in	  other	  parameters	  existed.	  When	  patients	  (n=22)	  
treated	   in	  the	  Helsinki	  University	  Hospital	  Cardiac	  Surgical	   ICU	  (not	  a	  member	  of	   the	  
Finnish	  Intensive	  Care	  Consortium	  in	  2007-­‐2008	  and	  patients	  not	  included	  in	  study	  II)	  
were	   excluded,	   only	   differences	   in	   the	   SAPS	   II	   score	   and	   hospital	   stay	   remained	  
significant:	  The	  median	  (IQR)	  SAPS	  II	  score	  was	  48	  (37-­‐62)	  in	  study	  II	  vs.	  53	  (41-­‐66)	  in	  
study	  IV	  (P=0.001)	  and	  hospital	  stay	  (days)	  was	  16	  (8-­‐29)	  in	  study	  II	  vs.	  14	  (5-­‐27)	  in	  
study	  IV,	  (P=0.013).	  (unpublished	  data)	  
5.4 RENAL REPLACEMENT THERAPY (II, IV) 
The	  indications	  for	  initiating	  RRT	  are	  presented	  in	  Table	  8.	  The	  median	  (IQR)	  number	  
of	  reported	  indications	  was	  3	  (2-­‐4)	  (IV).	  The	  median	  (IQR)	  RRT	  initiation	  day	  was	  1	  (1-­‐
2)	  in	  both	  studies,	  and	  did	  not	  significantly	  differ	  between	  studies	  II	  and	  IV	  (P=0.064)	  
(Figure	  4).	  	  
 
Table 8. Indications for RRT initiation (IV). 
 
 No./total no. (%) 
Oliguria 223/286 (78.0) 
High creatinine 196/279 (70.3) 
Acidosis 181/278 (65.1) 
Fluid accumulation 116/270 (43.0) 
Hyperkalemia 72/270 (26.7) 
Rhabdomyolysis 34/256 (13.3) 
Intoxication 19/265 (7.2) 





Figure 4. ICU treatment day of RRT initiation in studies II and IV. 
The	   initial	   RRT	  modalities	   in	   study	   IV	   are	   presented	   in	   Table	   9	   (IV).	   Of	   the	   215	  
patients	   initially	   receiving	   CRRT,	   regional	   citrate	   anticoagulation	   was	   used	   in	   127	  
(59.1%),	  low	  molecular	  weight	  heparins	  in	  61	  (28.5%),	  and	  unfractionated	  heparin	  in	  
2	   (0.9%),	   and	   CRRT	   was	   initiated	   without	   anticoagulation	   in	   25	   (11.6%)	   patients	  
(unpublished	  data).	  	  
The	  median	   (IQR)	   initially	   prescribed	   CRRT	   dose	   was	   35.3	   (31.2-­‐40.6)	   mL/kg/h	  	  
(Figure	  5)	  (IV).	  The	  median	  (IQR)	  daily	  duration	  recorded	  in	  680	  CRRT	  treatment	  days	  
was	  19	  (9.3-­‐24.0)	  hours,	  and,	  thus,	  the	  CRRT	  dose	  adjusted	  for	  duration	  treatment	  was	  
27.9	  mL/kg/h.	  The	  most	  common	  reasons	  for	  interruptions	  in	  therapy	  (reported	  from	  
137	  CRRT	  treatment	  days)	  were	  circuit	  clotting	  in	  70	  (51.1%),	  procedure	  31	  (22.6%),	  
surgery	  in	  19	  (13.9%)	  and	  technical	  problems	  in	  17	  (12.4%)	  (unpublished	  data).	  The	  
median	  (IQR)	  duration	  of	  CRRT	  was	  3	  (2-­‐6)	  days	  (data	  from	  230	  patients)	  and	  number	  
of	  IRRT	  sessions	  2	  (1-­‐4)	  (data	  from	  163	  patients)	  (IV).	  	  
	  
Table 9. Initial RRT modality (IV). 
 
 Number (%) 
Continuous RRT 215/296 (72.6) 
Continuous venovenous hemodialysis 111 (51.6) 
Continuous venovenous hemodiafiltration 93 (43.3) 
 -predilution -88 (94.6) 
Continuous venovenous hemofiltration 11 (5.1) 
 -predilution - 10 (90.9) 
Intermittent RRT 81/296 (27.4) 
Intermittent hemodialysis 62 (76.5) 
Sustained low-efficiency dialysis 11 (13.6) 
Molecular absorbent recirculating system 4 (4.9) 





Figure 5. Distribution of the initial prescribed continuous renal replacement therapy (CRRT) 
dose. 
5.5 OUTCOME  
5.5.1 MORTALITY (II, IV) 
The	  hospital,	  90-­‐day,	  and	  six-­‐month	  mortality	  rates	  of	  patients	  in	  studies	  II	  and	  IV	  are	  
presented	  in	  Table	  10.	  Of	  all	  1981	  included	  RRT-­‐treated	  patients,	  685	  (34.6%;	  95%	  CI	  
32.5-­‐36.7%)	  died	  in	  hospital.	  In	  study	  IV,	  non-­‐survivors	  were	  older	  [median	  (IQR)	  age	  
70	  (58-­‐77)	  vs.	  62	  (50-­‐69),	  P<0.001],	  had	  higher	  SAPS	  II	  scores	  [63	  (51-­‐77)	  vs.	  46	  (36-­‐
56),	   P<0.001],	   and	  had	   severe	   sepsis	  more	   frequently	   (59.5%	  vs.	   40.6%,	  P=0.002).	  A	  
comparison	  of	  survivors	  and	  non-­‐survivors	  regarding	  parameters	  at	  RRT	   initiation	   is	  




Table 10. Outcome of patients with or without RRT in study II and patients in study 
IV. 
 
 Study II Study IV 
 Non-RRT N=23218 RRT N=1686 RRT N=296 
Hospital mortalitya 3604/23202  
15.5% (15.0-16.0%) 
589/1685  
35.0% (32.7-37.3%)  
96/296  
32.4% (31.9-32.9%) 
90-day mortality    116/296  
39.2% (38.6-39.8%) 





SAPS II based SMR  
– (95% CI) 
0.61 (0.59-0.63) 0.76 (0.70-0.82) 0.64 (0.52-0.78) 
Mortality rates expressed as number/total number % (95% CI).  
SAPS; Simplified Acute Physiology Score, SMR; standardized mortality ratio 
a Comparison between non-RRT and RRT patients in study II, P<0.001 
 
 













SOFA score  290 9 [6-11]  12 [9-14]  <0.001 
Renal SOFA score  290 3 [1-4]  4 [2-4]  0.022 
Cumulative balance (L)a 283 3.1 [0.3-6.4] 6.2 [2.2-9.7]  <0.001 
Fluid accumulation (%)a  283 3.6 [0.3-8.2] 8.0 [3.0-12.9]  <0.001 
Urine output mL/24h  278 510 [157-1701]  150 [35-496]  <0.001 
Received diuretics prior to 
RRT initiation 
296 117/180 (65.0%) 85/116 (73.3%) 0.160 
Received colloids prior to 
RRT initiation  
290 114/177 (64.4%) 94/113 (83.2%) <0.001 
Creatinine (µmol/L)  290 279 [169-506]  237 [164-336]  0.049 
Lactate (mmol/L)  276 1.8 [1.1-4.8]  3.8 [1.7-8.0]  <0.001 
pH  291 7.31 [7.20-7.38]  7.25 [7.17-7.37]  0.072 
Base excess (mmol/L)  292 -7.6 [-13.0- -3.4]  -10.0 [-13.9- -5-1]  0.046 
Time from ICU admission 
to RRT initiation (hours)  
290 10.9 [2.5-42.1] 
 
19.2 [6.3-41.3]  0.044 
Continuous RRT as initial 
modality 
296 121/180 (67.2%) 94/116 (81.0%) 0.011 
 
Continuous data expressed as median [IQR] and categorical data as number/total number 
(%). 
SOFA; Simplified Acute Physiology Score 




5.5.2 RENAL RECOVERY (IV) 
Data	  on	  RRT	  need	  at	  90	  days	  were	  available	  from	  168	  survivors,	  of	  which	  34	  (18.9%,	  
95%	  CI	  13.2-­‐24.6%)	  were	  still	  dependent	  on	  RRT.	  Renal	  recovery	  rate	  seemed	  higher	  
among	  patients	  initially	  treated	  with	  CRRT,	  82.3%	  (93	  of	  113)	  compared	  to	  74.5%	  (41	  
of	  55)	  with	  IRRT,	  but	  the	  difference	  was	  not	  statistically	  significant	  (P=0.306).	  
5.5.3 HEALTH-RELATED QUALITY OF LIFE (II) 
Of	   the	   716	   6-­‐month	   survivors	   who	   received	   RRT	   during	   ICU	   stay,	   data	   regarding	  
HRQOL	  were	  available	   from	  313	   (44%)	  patients.	  Patients	  without	  HRQOL	  data	  at	   six	  
months	  were	  less	  severely	  ill	  [median	  (IQR)	  SAPS	  II	  score	  of	  40	  (28-­‐50)	  vs.	  45	  (35-­‐55),	  
P<0.001],	  younger	  [median	  (IQR)	  age	  59	  (47-­‐67)	  vs.	  61	  (50-­‐71),	  P=0.005),	  had	  shorter	  
median	  ICU	  stay	  (4.6	  (1.6-­‐10.6)	  vs.	  5.9	  (2.0	  -­‐11.6)	  days,	  P=0.045]	  and	  were	  more	  often	  
admitted	  electively	  (12%	  vs.	  6%,	  P=0.007)	  than	  those	  with	  data	  (unpublished	  data).	  	  
RRT	   patients	   had	   significantly	   lower	   HRQOL	   as	   measured	   with	   the	   EQ-­‐5D	   index	  
than	   patients	   without	   RRT	   at	   six	   months	   (Table	   12).	   Patients	   with	   RRT	   had	   more	  
frequently	   difficulties	   in	  mobility,	   self-­‐care	   and	   usual	   activities,	   but	   regarding	   bodily	  
pain	   and	   anxiety	   or	   depression	   no	   statistically	   significant	   differences	   were	   found.	  
According	   to	   the	   VAS,	   RRT	   patients	   perceived	   their	   own	   health	   status	   as	   good	   as	  
patients	  without	  RRT	  at	  six	  months	  (Table	  12).	  
 








EQ-5D index at baseline  
– median [IQR] – no./total no. (%) 
0.69 (0.53-1.0)  
7487 / 13266 (56.4%) 
0.68 (0.49-1.0)  
431/716 (60.2%) 
0.004 
EQ-5D index at six months  
– median [IQR] – no./total no. (%) 
0.68 (0.52-1.0)  
5415 /13266 (40.8%) 
0.63 (0.49-0.79)  
313/716 (43.7%) 
0.015 
VAS at baseline  
– median [IQR] – no./total no. (%) 
70 (50-80)  
4505 /13266 (34.0%) 
60 (40-80)  
223/716 (31.1%) 
0.009 
VAS at six months 
– median [IQR] – no./total no. (%) 
70 (55-85)  
4841/13266 (36.5%) 




VAS; visual analogue scale 
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5.6 FACTORS ASSOCIATED WITH OUTCOME 
5.6.1 GENERAL (II, IV) 
The	   results	   of	   logistic	   regression	   models	   for	   hospital	   mortality	   (II)	   and	   90-­‐day	  
mortality	  (IV)	  are	  summarized	  in	  Table	  13.	  SAPS	  II	  score	  (II)	  and	  SAPS	  II	  score	  without	  
age	  points	  and	  age	  as	  a	  separate	  variable	  (IV)	  were	  found	  to	  be	  associated	  with	  worse	  
outcome.	  In	  study	  II,	  the	  SOFA	  score	  did	  not	  remain	  significant	  in	  a	  preliminary	  model,	  
and	   was	   replaced	   with	   more	   organ	   specific	   variables.	   Non-­‐renal	   SOFA	   score	   was	  
significantly	   associated	  with	   an	   increased	   risk	   for	  mortality	   in	   study	   IV.	   Presence	   of	  
severe	  sepsis	  was	  significantly	  associated	  with	  an	  increased	  risk	  for	  mortality	  in	  study	  
II,	  but	  not	   in	  study	   IV.	  Higher	  creatinine	  on	   ICU	  admission	  day	  was	  associated	  with	  a	  
decreased	  risk	  for	  mortality	  in	  study	  II,	  but	  creatinine	  prior	  to	  RRT	  initiation	  was	  not	  
significantly	   associated	  with	   an	   increased	   risk	   for	  mortality	   in	   study	   IV.	   Longer	   time	  
from	   hospital	   admission	   to	   ICU	   admission	  was	   associated	  with	   an	   increased	   risk	   for	  
mortality	  (II).	  Time	  from	  ICU	  admission	  to	  RRT	  initiation	  was	  not	  significant	  (IV).	  	  
 
Table 13. Factors significantly associated with outcome in logistic regression.  
 




Study IIa for hospital mortality   
SAPS II score /point 1.056 (1.048-1.065) <0.001 
Time from hospital admission to ICU admission / 
day 
1.055 (1.029-1.081) <0.001 
Plasma creatinine (µmol/L)b 0.998 (0.997-0.999) <0.001 
Presence of severe sepsis 1.467 (1.135-1.894) 0.003 
   
Study IVc for 90-day mortality   
SAPS II score without age points /point 1.048 (1.024-1.074) <0.001 
Age (years) /year 1.046 (1.019-1.074) 0.001 
Non-renal SOFA scored /point 1.218 (1.075-1.380) 0.002 
Presence of fluid overload 2.626 (1.301-5.299) 0.007 
SAPS; Simplified Acute Physiology Score, SOFA; Sequential Organ Failure Assessment 
 
a Number of patients included in the model was 1557. Correct classification rate 72.5%. 
Hosmer-Lemeshow Chi-square test 5.8, P=0.673. Factors not significant in the model: 
ventilator treatment, vasoactive use, sex, operative admission. 
b  on ICU admission day 
c Number of patients included in the model was 242. Correct classification rate 74.5%, 
Hosmer-Lemeshow chi-square test 8.6, P=0.375. Area under the receiver operator 
characteristic curve (95% CI) 0.816 (0.767-0.866). Factors not significant in the model: time 
from ICU admission to RRT initiation (days), initial RRT modality (continuous or intermittent), 
lactate (mmol/L), base excess (mmol/L), and plasma creatinine (µmol/L) at RRT initiation, 
cumulative urine output on the day of RRT initiation, colloid use prior to RRT initiation 
(including data from ICU stay and 48h prior to ICU admission), presence of severe sepsis 
(yes/no) during the ICU admission. 
d  on day of renal replacement therapy initiation. 
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5.6.2 ICU SIZE AND ANNUAL CASE VOLUME (III) 
Annually,	  a	  median	  (IQR)	  case	  volume	  of	  patients	  treated	  with	  RRT	  for	  AKI	  was	  25	  (19-­‐
45)	  per	  ICU.	  The	  annual	  case	  volume	  in	  small	  vs.	   large	  ICUs	  and	  in	  volume	  tertiles,	  as	  
well	   as	   the	   patient	   characteristics	   and	   hospital	  mortality,	   are	   presented	   in	   Table	   14.	  
Patients	   in	   small	   or	   low-­‐volume	   ICUs	  were	   older,	   less	   severely	   ill,	   and	   received	   less	  
intensive	  treatment	  as	  measured	  with	  the	  TISS	  score.	  Crude	  hospital	  mortality	  was	  also	  
higher	  in	  small	  vs.	  large	  ICUs.	  After	  adjusting	  for	  age,	  SAPS	  II	  score	  without	  age	  points,	  
average	  TISS	  score,	  and	  day	  of	  RRT	  initiation,	  treatment	  of	  patients	  with	  RRT	  for	  AKI	  in	  
small	   ICUs	   was	   associated	   with	   an	   increased	   risk	   for	   hospital	   mortality	   [odds	   ratio	  
(95%	  CI)	  2.061	  (1.496-­‐2.840),	  P<0.001].	  	  
Mortality	   rates	   of	   patients	   treated	   in	   the	   ICUs	   classified	   into	   tertiles	   according	   to	  
the	  annual	  case	  volume	  are	  presented	  in	  Figure	  6.	  Treatment	  of	  patients	  with	  RRT	  for	  
AKI	   in	   low-­‐volume	   ICUs	  was	   associated	  with	   an	   increased	   risk	   for	  hospital	  mortality	  
compared	   to	   treatment	   in	   high-­‐volume	   ICUs	   after	   adjusting	   for	   age,	   SAPS	   II	   score	  
without	   age	   points,	   average	   TISS	   score,	   and	   day	   of	   RRT	   initiation	   [OR	   with	   95%	   CI	  
1.594	   (1.152-­‐2.206),	   P=0.005].	   After	   the	   same	   adjustments,	   treatment	   in	   medium-­‐
volume	   ICUs	  compared	   to	  high-­‐volume	   ICUs	  was	  associated	  with	  an	  odds	  ratio	   (95%	  
CI)	   of	   1.377	   (1.029-­‐1.844),	   P=0.032	   for	   increased	   risk	   for	   mortality.	   Propensity	   to	  
receive	  RRT	  did	  not	   remain	  significant	   in	  any	  of	   the	  models	   investigating	  association	  
between	  ICU	  size	  or	  annual	  case	  volume	  and	  hospital	  mortality.	  	  
 
Figure 6. Crude, case-mix-, and SAPS II –adjusted hospital mortality rates (with 95% confidence 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.6.3 FLUID OVERLOAD (IV) 
Of	  283	  patients	  with	  complete	  data	  on	  fluid	  balance,	  76	  (26.9%)	  had	  fluid	  overload	  at	  
RRT	   initiation.	   Patients	   with	   fluid	   overload,	   compared	   to	   those	   without,	   had	   higher	  
SAPS	   II	   score	   [median	  (IQR)	  55	  (44-­‐77)	  vs.	  50	  (40-­‐63),	  P<0.001],	  experienced	  severe	  
sepsis	  more	  often	  (64.5%	  vs.	  42.5%,	  P=0.001),	  and	  had	  lower	  urine	  output	  on	  the	  day	  
of	   RRT	   initiation	   [median	   (IQR)	   164	   (35-­‐511)	  mL	   vs.	   429	   (110-­‐1531)	  mL,	   P<0.001].	  
They	  also	  reported	  a	   longer	  median	  (IQR)	  time	  from	  ICU	  admission	  to	  RRT	  initiation,	  
26.9	   (10.7-­‐43.7)	   h	   vs.	   9.3	   (2.5-­‐35.7)	   h,	   P<0.001	   and	   had	   CRRT	   as	   an	   initial	  modality	  
more	   frequently	   (92.1%	   vs.	   66.7%,	   P<0.001).	   Patients	   with	   fluid	   overload	   had	  
significantly	  higher	  crude	  90-­‐day	  mortality	   compared	   to	   those	  without,	  59.2%	  (45	  of	  
76)	  vs.	  31.4%	  (65	  of	  207),	  P<0.001.	  After	  adjustments,	  fluid	  overload	  at	  RRT	  initiation	  




6.1 QUALITY OF PHARMACOKINETIC STUDIES 
In	  the	  systematic	  review	  regarding	  the	  quality	  of	  published	  pharmacokinetic	  studies	  in	  
CRRT	   patients,	   the	   general	   quality	   of	   the	   included	   studies	   was	   moderate,	   while	   the	  
reporting	   of	   the	   characteristics	   of	   the	   CRRT	   treatment,	   as	   recommended	   by	   Acute	  
Dialysis	   Quality	   Initiative,124	   was	   poor.	   Almost	   half	   of	   the	   relevant	   original	   articles	  
found	  in	  the	  literature	  search	  had	  to	  be	  excluded	  because	  of	  the	  inadequate	  reporting	  
of	  CRRT	  parameters.	  The	  study	  inclusion	  criteria	  comprised	  one	  to	  three	  of	  the	  CRRT	  
characteristics,	  which	  caused	  selection	  bias.	  None	  of	  the	  included	  studies	  reported	  the	  
CRRT	  dose	  standardized	  to	  patient	  weight.	  Some	  studies	  standardized	  the	  effluent	  flow	  
rates,	   which,	   however,	   does	   not	   account	   for	   the	   patient	   size.	   Regarding	   patient	  
characteristics,	   half	   of	   the	   studies	   failed	   to	   report	   a	   disease	   severity	   score,	   which	  
impairs	  the	  ability	  to	  generalize	  from	  those	  studies.	  No	  improvement	  in	  reporting	  these	  
parameters	   after	   the	   publication	   of	   the	   Acute	   Dialysis	   Quality	   Initiative	   minimal	  
reporting	   criteria	   was	   detected.	   Correspondingly,	   regarding	   the	   reporting	   of	   cluster	  
randomized	  trials,	  the	  penetration	  of	  published	  recommendations	  have	  been	  observed	  
to	  be	   inadequate.108	  Our	   findings	  about	   inadequate	  reporting	  are	   in	   line	  with	  another	  
systematic	  review.141	  
The	  calculated	  CRRT	  dose	  used	  in	  the	  included	  studies	  was	  in	  line	  with	  the	  current	  
recommendations.114,120,	   114,235	  However,	  only	  a	   third	  of	   the	  studies	  reported	   the	  daily	  
duration	   of	   CRRT	   treatment,	   and	   as	   delivered	   dose	   may	   be	   20-­‐30%	   less	   than	  
prescribed	   due	   to	   interruptions,187,204,236,237	   it	   is	   likely	   that	   calculations	   in	   this	   study	  
overestimated	  the	  true	  delivered	  dose.	  Moreover,	  prescribing	  a	  dose	  of	  25-­‐30	  mL/kg/h	  
to	  compensate	  for	  interruptions	  is	  recommended,114,	  120,	  114,235	  and	  in	  only	  a	  third	  of	  the	  
included	  studies	  the	  calculated	  dose	  exceeded	  25	  mL/kg/h.	  	  
Recently,	   in	   a	   study	   where	   drug	   dosing	   was	   not	   standardized	   but	   the	   treating	  
clinician	  was	   responsible	   for	   the	   empirical	  drug	  dosing	   strategy,	   no	  differences	  were	  
found	  in	  the	  concentrations	  of	  several	  antibiotics	  in	  patients	  receiving	  CRRT	  either	  25	  
mL/kg/h	   or	   40	   mL/kg/h.207	   This	   work	   also	   demonstrated	   that	   the	   antibiotic	  
concentrations	   did	   not	   reach	   the	   target	   25%	   of	   time,	   possibly	   because	   of	   the	   wide	  
range	   of	   empirical	   drug	   dosing	   strategies	   used	   or	   variations	   in	   other	   properties	  
affecting	   drug	   clearance	   such	   as	   residual	   renal	   clearance.207	  Moreover,	   the	  measured	  
urea	  clearance	  has	  been	  reported	  to	  be	  25-­‐35%	  less	  than	  the	  estimated	  urea	  clearance	  
regarding	   doses	   30-­‐35	   mL/kg/h.52,150	   Regarding	   lower	   doses	   of	   20-­‐25	   ml/kg/h,	   the	  
reduction	   in	   the	   estimated	   clearance	   has	   been	   lower.150	   Thus,	   measuring	   urea	  
clearance,	  for	  example,	  to	  give	  an	  estimate	  of	  true	  small	  solute	  clearance,	  in	  addition	  to	  
reporting	   and	   standardizing	   the	   CRRT	   dose,	   would	   add	   value	   to	   the	   mainly	   well-­‐
recorded	  pharmacokinetic	  data.	  However,	  an	  individualized	  drug	  dosing	  strategy	  might	  
be	  the	  best	  way	  to	  tackle	  the	  complexities	  in	  drug	  dosing	  during	  CRRT.44	  	  	  
No	  other	  studies	  have	  screened	  the	  completeness	  of	  the	  minimal	  reporting	  criteria	  
recorded	  for	  CRRT	  studies	  by	  Acute	  Dialysis	  Quality	  Initiative.124	  Given	  the	  inadequate	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reporting	  of	  these	  criteria	  in	  pharmacokinetic	  studies,	  in	  which	  standardized	  dosing	  of	  
both	   the	   drug	   and	   the	   CRRT	   treatment	   should	   be	   self-­‐evident,	   the	   reporting	  may	   be	  
even	  more	  insufficient	  in	  other	  observational	  studies	  regarding	  CRRT.	  In	  study	  IV,	  data	  
were	  recorded	  for	  all	  six	  criteria	  about	  patient	  characteristics,	  but	  failed	  to	  record	  data	  
on	   vascular	   access,	   delivery	   device,	   and	   dialysis	   or	   replacement	   fluid	   composition	  
required	   in	   the	   operational	   criteria.	   However,	   patients	   receiving	   IRRT	   were	   also	  
included,	  and	  data	  regarding	  delivery	  device	  or	  used	  dialysate	  fluid	  could	  be	  obtained	  
from	  the	  manufacturer.	  	  
6.2 INCIDENCE OF RRT FOR AKI 
The	  population-­‐based	  incidence	  found	  in	  studies	  II	  and	  IV	  was	  19.4	  -­‐	  20.2	  per	  100	  000	  
adults	   per	   year	   and	  within	   the	  wide	   range	   of	   reports	   from	   other	   regions,	  where	   the	  
incidence	  rate	  has	  varied	  from	  4242	  to	  9636	  per	  100	  000	  per	  year.	  In	  a	  study	  by	  Cartin-­‐
Ceba	   et	   al.36	   the	   incidence	   of	   not	   only	   RRT	   but	   also	   other	   ICU	   syndromes	   was	  
exceptionally	   high,	   possibly	   because	   of	   a	   liberal	   ICU	   admission	   policy.	   Older	   studies	  
have	   reported	   lower	   incidence	   rates	   from	   4	   to	   8	   per	   100	   000,128,221,	   242	   and	   a	   rising	  
trend	   in	   the	   incidence	   has	   been	   found.242	   Compared	   to	   a	   Finnish	   single-­‐center	   study	  
conducted	   in	  1992-­‐1993,128	   the	  population-­‐based	   incidence	   in	  Finland	  has	   increased.	  
More	  recent	  studies	  have	  reported	  incidence	  rates	  from	  13.3	  to	  28.6.164,	  200,253	  A	  study	  
by	  Prescott	   et	   al.200	   also	   included	  patients	   treated	  outside	   the	   ICU.	  The	  proportion	  of	  
ICU	  patients	  treated	  with	  RRT	  for	  AKI	  in	  study	  II	  corresponded	  to	  other	  reports	  where	  
3	   to	  8%	  of	   general	   ICU	  patients	  have	   received	  RRT.12,55,105,165,196,231	  The	   ICU	   incidence	  
rate	   is,	  however,	  more	  prone	  to	  variations	  than	  population-­‐based	  incidence,	  since	  the	  
denominator	  depends	  on	  the	  admission	  policy	  of	  the	  ICU.	  
The	   population-­‐based	   incidence	   in	   Finnish	   hospital	   districts	   in	   study	   IV	  
corresponded	   mainly	   to	   the	   findings	   of	   study	   II.	   In	   study	   II,	   the	   population-­‐based	  
incidence	  was	   three	   times	   as	   high	   in	   the	   hospital	   district	  with	   the	   highest	   incidence	  
rate	   compared	   to	   the	  district	  with	   the	   lowest	   rate.	   The	  hospital	   districts	  with	  higher	  
incidence	  rates	  had	  small	  central	  hospitals,	  and	  it	  is	  possible	  that	  indications	  for	  RRT	  as	  
well	   as	   ICU	  admission	  policies	  may	  be	  different	   from	   that	  of	  university	  hospitals	  and	  
larger	  central	  hospitals.	  Greater	  variations	  in	  the	  population-­‐based	  incidence	  in	  smaller	  
hospital	   districts	   were	   also	   found	   in	   study	   IV.	   This	   finding	   may	   also	   be	   due	   to	   the	  
shorter	  study	  period	  of	  study	  IV	  compared	  to	  study	  II.	  	   	  
6.3 RENAL REPLACEMENT THERAPY 
In	   study	   IV,	   a	  median	  of	   three	   indications	   for	   initiating	  RRT	  was	   reported.	  The	  more	  
indications	  for	  RRT	  are	  present,	  the	  higher	  the	  mortality	  has	  been	  shown	  to	  be.16	  As	  in	  
the	   multinational	   BEST	   study,230	   the	   most	   common	   indications	   were	   oliguria,	   high	  
creatinine,	   metabolic	   acidosis,	   and	   fluid	   accumulation.	   Hyperkalemia	   was	   reported	  
more	  frequently	  than	  in	  other	  studies.204,230	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RRT	   was	   initiated	   early	   in	   both	   studies	   II	   and	   IV.	   The	   median	   time	   from	   ICU	  
admission	   to	   RRT	   initiation	  was	   one	   day,	   and	   61-­‐66%	   of	   patients	   had	   RRT	   initiated	  
within	  the	  first	  24	  hours	  of	  ICU	  treatment.	  Few	  observational	  studies	  have	  reported	  as	  
early	   initiation	   in	   terms	   of	   time	   from	   ICU	   admission.15,16	   In	   the	   BEST	   study,15	   the	  
median	   time	   to	  RRT	   initiation	   in	  days	  was	   corresponding	   to	   that	  described	  here,	  but	  
only	  half	  of	  the	  patients	  were	  initiated	  on	  RRT	  within	  the	  first	  ICU	  treatment	  day.	  In	  the	  
study	   by	   Bagshaw	   et	   al.,16	   the	   median	   renal	   SOFA	   score	   at	   RRT	   initiation	   was	   4	  
compared	  to	  3	  in	  study	  IV;	  median	  urine	  output	  was	  slightly	  less	  and	  serum	  creatinine	  
higher	  at	  RRT	   initiation	   than	   in	   the	  present	   study.	  This	   finding	  could	   imply	   that	  RRT	  
was	  initiated	  earlier	  in	  our	  study	  in	  terms	  of	  development	  of	  AKI.	  However,	  in	  the	  study	  
by	   Bagshaw	   et	   al.,16	   only	   30%	   of	   the	   patients	   had	   received	   diuretics	   prior	   to	   RRT	  
initiation	   compared	   to	   almost	   70%	   in	   the	   present	   study,	   which	   may	   cause	   bias	   in	  
assessing	  the	  urine	  output.	  In	  most	  other	  reports,	  RRT	  has	  been	  initiated	  much	  later,	  a	  
median	  of	  two	  to	  seven	  days	  from	  ICU	  admission.204,	  143,151	  187	  	  
CRRT	  was	   the	   initial	  modality	   in	   73%	   of	   patients	   in	   study	   IV	   as	   in	   several	   other	  
studies.16,143,253	   In	   the	   BEST	   study,15	   and	   in	   a	   Swedish	   retrospective	   cohort	   study,18	  
about	  85%	  of	  patients	  have	  received	  CRRT,	  while	  studies	  from	  the	  U.S.	  have	  reported	  
lower	  proportions	  of	   45-­‐56%.36,	   163	   CVVHD	  and	  CVVHDF	  were	   the	  mostly	  used	  CRRT	  
modalities.	   Regional	   citrate	   anticoagulation	   was	   used	   in	   60%	   of	   patients	   receiving	  
CRRT.	   	   In	   the	   BEST	   study	   conducted	   in	   2000,	   citrate	   was	   used	   in	   only	   10%	   of	  
patients,230	   which	   may	   be	   because	   regional	   citrate	   anticoagulation	   was	   introduced	  
rather	   recently.162	   However,	   by	   2011,	   it	   seems	   to	   have	   been	   well	   implemented	   into	  
clinical	  practice	  at	  least	  in	  Finland.	  	  
The	   median	   daily	   duration	   of	   CRRT	   treatment	   in	   this	   study	   was	   19	   hours,	  
somewhat	   lower	   than	   reported	   in	   a	   RCT,187	   whilst	   the	   prescribed	   CRRT	   dose	   was	  
higher	  than	  the	  dose	  of	  20	  mL/kg/h	  reported	  in	  the	  BEST	  study.230	  The	  prescribed	  dose	  
in	   the	   present	   study	   was	   slightly	   higher	   than	   the	   current	   recommendation	   of	  
prescribing	  a	  dose	  of	  25-­‐30	  mL/kg/h	  to	  target	  a	  delivered	  dose	  of	  20-­‐25	  mL/kg/h.120	  
However,	   after	   adjusting	   for	   treatment	   interruptions,	   the	  median	   CRRT	  dose	  was	   28	  
mL/kg/h,	  in	  line	  with	  the	  current	  recommendations.120	  
6.4 OUTCOME 
6.4.1 MORTALITY 
The	   hospital	   mortality	   rates	   observed	   in	   studies	   II	   and	   IV	   were	   high	   among	   ICU	  
patients	   in	   general,	   but	   lower	   than	   in	   previous	   studies	   with	   RRT	   patients	   with	  
corresponding	   patient	   characteristics	   and	   disease	   severity.67,165,179,230	   Both	   90-­‐day	  
mortality	   and	   6-­‐month	   mortality	   rates	   were	   lower	   than	   in	   previous	  
reports.18,128,204,143,200	   Several	   studies	   with	   markedly	   higher	   disease	   severity	   have	  
reported	  higher	  mortality	  rates	   in	  hospital,184	  at	  90	  days,59,241	  and	  at	  6	  months.59	  The	  
SAPS	  II	  -­‐based	  SMR	  of	  0.64-­‐0.76	  showed	  that	  mortality	  rates	  were	  lower	  than	  would	  be	  
expected	   based	   on	   the	   SAPS	   II	   prediction	   model.	   The	   hospital	   mortality	   observed	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among	  patients	  with	  RRT	  was	  higher	  than	  in	  a	  previous	  Finnish	  study	  among	  patients	  
with	   severe	   sepsis,117	   while	   the	   90-­‐day	   mortality	   was	   corresponding	   to	   Finnish	  
patients	  with	   acute	   lung	   injury	  or	   acute	   respiratory	  distress	   syndrome.144	   In	   general,	  
disease	   severity	   was	   found	   to	   be	   associated	   with	   hospital	   or	   90-­‐day	   mortality	   in	  
studies	   II	   and	   IV.	   The	   significance	   of	   other	   factors	   (e.g.	   creatinine	   prior	   to	   RRT)	  
depends	  a	  great	  deal	  on	  the	  strength	  of	  other	  factors	  entered	  in	  the	  logistic	  regression	  
model.	  	  
Several	   potential	   explanatory	   factors	   for	   the	   observed	   better	   outcome	   exist.	   The	  
outcome	  of	  all	  ICU	  patients	  treated	  in	  Finland	  has	  been	  shown	  to	  be	  rather	  good,	  and	  to	  
improve	   over	   time.203	   The	   SAPS	   II	   –based	   SMR	   in	   2005-­‐2008	   among	   all	   Finnish	   ICU	  
patients	   was	   0.64,203	   corresponding	   to	   the	   SMR	   calculated	   in	   the	   study	   IV	   for	   RRT	  
patients	   only.	   Patient	   characteristics	   were	   corresponding	   in	   studies	   II	   and	   IV	   (after	  
excluding	  the	  patients	  treated	  in	  the	  cardiac	  surgical	  ICU	  in	  study	  IV)	  and	  the	  timing	  of	  
RRT	  did	  not	  differ	  between	  these	  studies.	  Thus,	  data	  on	  RRT	  dose	  and	  modality	   from	  
study	   IV	   are	   likely	   to	   also	   apply	   to	   study	   II,	   given	   that	   large	   changes	   in	   treatment	  
practices	   over	   few	   years	   are	   unlikely.	   The	   CRRT	   dose	   employed	   in	   study	   IV	   was	  
according	  to	  recommendations,	  in	  contrast	  to,	  the	  BEST	  study	  for	  example,	  where	  the	  
observed	   CRRT	   dose	  was	   lower	   than	   recommended.230	   RRT	  was	   also	   initiated	   early,	  
within	   a	   median	   of	   one	   day	   from	   ICU	   admission.	   In	   studies	   that	   have	   reported	   a	  
corresponding	   median	   time	   from	   ICU	   admission	   to	   RRT	   initiation,	   the	   hospital	  
mortality	  rates	  were	  62%	  despite	  corresponding	  SAPS	  II	  and	  SOFA	  scores15	  and	  52%	  
with	  slightly	  higher	  SOFA	  scores	  on	  the	  day	  of	  RRT	  initiation16	  than	  in	  the	  study	  IV.	  In	  
the	  study	  by	  Bagshaw	  et	  al.16	  the	  used	  CRRT	  dose	  was	  not	  reported.	  	  	  
Very	   early	   initiation	   of	   RRT	   could	   possibly	   mean	   that	   some	   patients	   who	   would	  
recover	  without	  RRT	  if	  a	  “wait	  and	  see”	  -­‐approach	  would	  be	  used	  are	  initiated	  on	  RRT	  
unnecessarily.180	   A	   study	   including	   patients	   with	   RIFLE-­‐Failure	   AKI	   who	   did	   not	  
receive	   RRT	   showed	   that	   the	   mortality	   and	   disease	   severity	   of	   these	   patients	   were	  
lower	  than	  that	  of	  RIFLE-­‐Failure	  patients	  with	  RRT.217	  Regarding	  our	  study,	  the	  disease	  
severity	  was	  comparable	  with	  other	   reports,	  patients	  had	  a	  median	   three	   indications	  
for	  RRT,	  and	  the	  population-­‐based	  incidence	  was	  in	  line	  with	  other	  reports.	  Thus,	  the	  
timing	  of	  RRT	  in	  our	  study	  is	  unlikely	  to	  be	  too	  early.	  
6.4.2 RENAL RECOVERY 
Of	  90-­‐day	  survivors	   in	  study	   IV,	  only	  81%	  recovered	  to	  be	   independent	  of	  RRT	  at	  90	  
days.	   Renal	   recovery	   rate	   at	   90	   days	   has	   been	   reported	   to	   vary	   from	   75%	   to	  
96%.18,204,143,164,211	   The	   recovery	   rate	   in	   this	   study	   is	   thus	   among	   the	   lowest,	   possibly	  
because	   of	   the	   lower	   mortality	   rate,	   and	   more	   surviving	   patients.	   Furthermore,	   the	  
proportion	   of	   patients	   receiving	   IRRT	  was	   higher.	   The	   use	   of	   CRRT	   has	   been	   linked	  
with	   better	   renal	   recovery,18	  whilst	   the	   non-­‐recovery	   of	   renal	   function	   increases	   the	  




6.4.3 HEALTH-RELATED QUALITY OF LIFE 
Among	  cancer	  patients,	  a	  clinically	  significant	  difference	   in	   the	  EQ-­‐5D	  score	  has	  been	  
reported	   to	   be	   0.06-­‐0.08	   and	   7	   in	   VAS.198	   According	   to	   these	   criteria,	   no	   clinically	  
significant	   difference	   in	   HRQOL	   measured	   with	   the	   EQ-­‐5D	   index	   at	   six	   months	   in	  
patients	  with	  and	  without	  RRT	  was	  observed	  in	  study	  II.	  Of	  the	  five	  dimensions	  of	  the	  
EQ-­‐5D	   index,	   patients	  with	  RRT	  had	   slightly	   lower	   scores	   for	   dimensions	   of	   physical	  
health,	   but	   no	   significant	   differences	   regarding	   mental	   health	   were	   observed.	   A	  
previous	   study	   supports	   these	   findings.59	   A	   lower	   HRQOL	   among	   RRT	   patients	  
compared	  to	  matched	  general	  population	  has	  been	  reported,	  but	  the	  HRQOL	  of	  patients	  
with	   RRT	   was	   not	   compared	   to	   ICU	   patients	   without	   RRT.59,258	   One	   study	   using	   the	  
health	  utilities	  index	  found	  an	  extremely	  low	  HRQOL	  in	  a	  quarter	  of	  patients	  with	  RRT,	  
corresponding	   to	   a	   situation	   equal	   or	  worse	   than	  death	   in	   the	   general	   population.112	  
This	  finding	  is	  in	  contrast	  to	  the	  results	  of	  other	  studies	  that	  have	  found	  RRT	  patients	  
to	   be	  willing	   to	   undergo	   the	   same	   treatment	   again	   if	   necessary.59,90	  Moreover,	   in	   the	  
present	   study,	   RRT	   patients’	   perception	   of	   their	   own	   health	   according	   to	   the	   VAS	  
corresponded	   to	   the	  perception	  of	  patients	  without	  RRT	  and	   the	  previously	   reported	  
values	  of	  the	  general	  population.258	  
6.5 ASSOCIATION OF ICU SIZE AND ANNUAL CASE 
VOLUME WITH OUTCOME 
The	   crude	   mortality	   of	   patients	   treated	   in	   large	   ICUs	   was	   lower	   compared	   to	   small	  
ICUs.	   The	   difference	   remained	   after	   adjusting	   for	   age,	   disease	   severity,	   intensity	   of	  
treatment,	  and	  day	  of	  RRT	  initiation.	  Patients	   in	  small	   ICUs	  receiving	  RRT	  were	  older	  
but	  less	  severely	  ill,	  implying	  potential	  differences	  in	  indications	  for	  RRT.	  To	  control	  for	  
the	   potential	   differences	   in	   assigning	   patients	   to	   RRT,	   a	   propensity	   score	   was	  
generated,	  which	   did	   not	   remain	   significant	   in	   any	   of	   the	   logistic	   regression	  models.	  
Organizational	   factors	   have	   been	   described	   as	   one	   traditional	   explanation	   for	   the	  
volume-­‐outcome	   effect.115	   They	   may	   partly	   account	   for	   the	   observed	   difference	   in	  
outcome	   in	   the	   small	   vs.	   large	   ICUs.	   Small	   ICUs	   in	   small	   hospitals	   may	   have	   more	  
limited	  resources	  for	  out-­‐of-­‐office	  hour	  surgical	  expertise	  and	  radiological	  procedures,	  
for	  example.	   	  
The	  median	  annual	  case	  volume	  of	  25	  patients	  receiving	  RRT	  for	  AKI	  in	  all	  ICUs	  that	  
was	  observed	  in	  this	  study	  was	  rather	  low.	  Other	  reports	  regarding	  annual	  volume	  of	  
RRT-­‐treated	  patients	  are	  few,	  however.	  Nguyen	  et	  al.174	  reported	  a	  median	  annual	  case	  
volume	  of	  29	  in	  a	  French	  cohort	  and	  only	  17	  in	  a	  U.S.	  cohort.	  The	  annual	  case	  volumes	  
of	   RRT	   treated	   patients	   both	   in	   the	   present	   study	   and	   in	   the	   study	   of	   Nguyen	   and	  
colleagues	   are	   much	   lower	   compared,	   for	   example,	   to	   a	   study	   regarding	   volume	  
outcome	  effect	  in	  patients	  receiving	  mechanical	  ventilation.116	  
After	  adjusting	  for	  disease	  severity,	  patient	  age,	   intensity	  of	  care,	  and	  time	  of	  RRT	  
initiation,	  treatment	  in	  low-­‐	  or	  medium	  annual	  case	  volume	  ICUs	  was	  associated	  with	  
increased	  risk	  for	  hospital	  mortality	  compared	  to	  treatment	  in	  high	  volume	  ICUs.	  This	  
finding	   is	   in	   contrast	   to	   the	   study	  by	  Nguyen	   et	   al.,174	  where	   two	   large	   cohorts	  were	  
 
 63	  
divided	   into	   quartiles,	   and	   no	   association	   between	   annual	   case	   volume	   and	   outcome	  
was	   found	   after	   adjusting	   for	   disease	   severity,	   admission	   diagnosis,	   time	   in	   hospital	  
preceding	  ICU	  admission	  and	  ICU	  characteristics.	  Notably,	  they	  had	  a	  long	  study	  period	  
of	  ten	  years	  which	  was	  not	  adjusted	  for,	  and	  as	  treatment	  results	  of	  ICU	  care	  have	  been	  
shown	  to	  improve	  over	  time203	  and	  mortality	  of	  AKI	  to	  decrease11	  the	  long	  study	  period	  
may	  have	  influenced	  the	  results	  of	  their	  study.	  In	  contrast,174	  ICUs	  in	  the	  present	  study	  
were	  unselected	  and	  the	  findings	  are	  in	  line	  with	  those	  from	  other	  ICU	  patient	  groups	  
demonstrating	  the	  presence	  of	  a	  likely	  volume-­‐outcome	  effect.116,192,257	  	  
6.6 ASSOCIATION OF FLUID OVERLOAD WITH 
OUTCOME 
Patients	  with	   fluid	  overload	   at	  RRT	   initiation	  had	   almost	   twice	   as	  high	   crude	  90-­‐day	  
mortality	  compared	  to	  those	  without.	  The	  difference	  remained	  after	  adjusting	  for	  age,	  
disease	   severity,	   initial	   RRT	   modality,	   presence	   of	   severe	   sepsis,	   time	   from	   ICU	  
admission	  to	  RRT	  initiation,	  and	  several	  other	  factors.	  In	  critically	  ill	  children,	  a	  strong	  
association	  between	  fluid	  overload	  at	  RRT	  initiation	  and	  increased	  mortality	  has	  been	  
shown.89,227	   Among	   adult	   patients,	   fluid	   accumulation	   of	   5%	   calculated	   from	   24h	  
preceding	   RRT	   initiation16	   or	   10%	   three	   days	   preceding	   a	   nephrologist	   consultation	  
(time	   from	   consultation	   to	   RRT	   initiation	   not	   defined)25	   have	   been	   associated	   with	  
increased	  mortality.	   A	   small	   prospective	   study82	   and	   a	   retrospective	   study	   that	   also	  
included	   patients	   treated	   outside	   the	   ICU,99	   have	   used	   weight	   gain	   from	   baseline	  
(preceding	  critical	  illness)	  to	  RRT	  initiation	  to	  define	  fluid	  overload	  and	  have	  reported	  
corresponding	  results.	  Additionally,	  more	  positive	  mean	  daily	   fluid	  balance	  after	  RRT	  
initiation	  has	  been	  associated	  with	  increased	  mortality.205	  
More	   severely	   ill	   patients	   typically	   require	   larger	   amounts	   of	   fluid	   in	   the	   initial	  
resuscitation	   phase	   of	   critical	   illness.	   A	   higher	   degree	   of	   fluid	   accumulation	   at	   RRT	  
initiation	   might	   reflect	   the	   overall	   severity	   of	   illness,	   and	   fluid	   balance	   has	   been	  
proposed	   as	   a	   biomarker	   of	   critical	   illness.9	   In	   the	   present	   study,	   patients	  with	   fluid	  
overload	   had	   higher	   SAPS	   II	   and	   SOFA	   scores,	   had	   severe	   sepsis	  more	   often,	   higher	  
lactate	   values,	   and	   lower	   urine	   output	   prior	   to	   RRT	   initiation	   compared	   to	   those	  
without.	  The	  association	  of	   fluid	  overload	  with	   increased	  risk	  for	  mortality	  remained,	  
however,	  after	  adjusting	  for	  all	  these	  parameters,	  and,	  consequently,	  severity	  of	  illness	  
is	   unlikely	   to	   solely	   account	   for	   these	   findings.	  On	   the	  other	  hand,	  RRT	  was	   initiated	  
later	   among	   patients	   with	   fluid	   overload,	   meaning	   that	   they	   had	   more	   time	   to	  
accumulate	  fluid,	  but	  again,	  the	  difference	  in	  outcome	  remained	  after	  adjusting	  for	  time	  
of	  RRT	  initiation.	  Earlier	  RRT	  initiation	  in	  terms	  of	  time,	  and	  thus	  probably	  also	  with	  a	  
lower	  degree	  of	  fluid	  accumulation,	  might	  have	  altered	  the	  outcome	  of	  these	  patients.	  A	  
threshold	   value	  of	   10%	   fluid	  overload	   for	   the	  use	  of	   diuretics	   or	  RRT	   initiation	   after	  
initial	  resuscitation	  phase	  is	  included	  in	  the	  current	  recommendations	  for	  management	  






Several	   limitations	   in	   these	   studies	   should	   be	   addressed.	   In	   study	   I,	   assumptions	  
regarding	   patients’	   fluid	   balance	   or	   hematocrit	   had	   to	   be	   made	   in	   a	   third	   of	   the	  
included	   studies	   to	   calculate	   the	   CRRT	   dose.	   Missing	   data,	   varying	   patient	  
characteristics,	   and	   differences	   in	   the	   provided	   CRRT	  made	   statistical	   comparison	   of	  
the	  included	  studies	  impossible.	  	  
Regarding	   studies	   II-­‐IV,	   inherent	   limitations	   of	   observational	   studies	   apply.	   The	  
observed	  associations	  do	  not	  prove	  causality.	  Moreover,	  although	  a	  number	  of	  factors	  
in	   each	   study	   were	   adjusted	   for,	   it	   may	   be	   possible	   that	   something	   that	   was	   not	  
measured	   affected	   outcome.	   Hospital	   mortality	   used	   as	   an	   endpoint	   in	   the	   logistic	  
regression	  models	  in	  studies	  II	  and	  III	  is	  not	  a	  recommended	  endpoint,88	  however,	  the	  
results	  of	  study	  III	  were	  robust	  for	  sensitivity	  analysis	  performed	  by	  excluding	  patients	  
discharged	   to	   other	   ICUs.	   In	   study	   IV,	   a	   fixed	   endpoint	   at	   90	   days	   was	   used	   as	  
recommended.88	   The	   retrospective	   design	   of	   studies	   II	   and	   III	   is	   a	   further	   limitation,	  
however,	  the	  used	  dataset	  was	  comprised	  of	  prospectively	  recorded	  data.	  
In	   studies	   II	   and	   IV,	   data	   on	   RRT	   administered	   outside	   ICUs	   were	   not	   included.	  
However,	  RRT	  for	  AKI	  outside	  ICUs	  in	  Finland	  is	  uncommon,	  and	  thus	  the	  bias	  caused	  
by	   this	   in	   the	  population-­‐based	   incidence	   is	   only	  minor.	  Regrettably,	   data	  on	  HRQOL	  
were	   available	   for	   only	   44%	   of	   six-­‐month-­‐survivors	  with	   RRT	   during	   their	   ICU	   stay,	  
which	  may	  have	   caused	  bias	   in	   study	   II.	  The	   respondents	  were	  older,	  were	  admitted	  
due	   to	  emergency	  more	  often,	   and	  had	  higher	  disease	   severity	  and	  a	   longer	   ICU	  stay	  
compared	  to	   the	  non-­‐respondents.	  Given	  that	   the	  patients	   lost	   to	   follow-­‐up	  were	   less	  
severely	   ill,	   the	   potential	   bias	   due	   to	   the	   low-­‐response	   rate	   is	   likely	   to	   cause	  
underestimation	  of	  HRQOL	  rather	  than	  overestimation.	  	  
Since	  the	  data	  in	  studies	  II	  and	  III	  were	  part	  of	  the	  routine	  dataset	  recorded	  of	  all	  
ICU	  patients,	  data	  regarding	  RRT	  indications,	  dose,	  and	  modality	  could	  not	  be	  obtained.	  
However,	   as	   the	   characteristics	   of	   the	   RRT	   patients	   in	   studies	   II	   and	   IV	   were	  much	  
alike,	   and	   treatment	   practices	   are	   unlikely	   to	   largely	   evolve	   in	   a	   few	   years,	   results	  
regarding	  the	  provided	  RRT	  in	  study	  IV	  could	  also	  be	  applied	  in	  studies	  II	  and	  III.	  	  
In	  study	  III,	  differences	  in	  the	  ICU	  admission	  and	  treatment	  restriction	  policies	  may	  
account	   for	   the	   observed	   differences	   in	   part.	   Furthermore,	   the	   study	   was	   probably	  
underpowered	  to	  detect	  a	  volume-­‐outcome	  effect	  in	  the	  crude	  mortality	  also	  between	  
the	  ICU	  volume	  tertiles.	  Due	  to	  the	  small	  population	  of	  Finland,	  the	  referral	  populations	  
and	  bed	  numbers	  of	  Finnish	  ICUs	  are	  small	  compared	  to	  other,	  more	  densely	  populated	  
countries.	   However,	   the	   results	   of	   this	   study	   are	   applicable	   to	   other	   small	   countries	  
with	  small	  ICUs.	  	  
Finally,	  the	  power	  of	  study	  IV	  was	  insufficient	  to	  assess	  factors	  associated	  with	  the	  
non-­‐recovery	   of	   renal	   function	   at	   90	   days.	   Moreover,	   data	   on	   the	   fluid	   balance	  
preceding	   ICU	   admission	   could	   not	   be	   recorded,	   however,	   unlike	   some	   previous	  





6.8 CLINICAL IMPLICATIONS 
 
These	  data	  may	  have	  following	  clinical	  implications:	  
 
Pronounced	   interpatient	   differences	   in	   the	   included	   studies	   about	   pharmacokinetics	  
during	   CRRT	   allowed	   neither	   the	   provision	   of	   new	   recommendations	   about	   drug	  
dosing	  nor	  statistical	  comparisons	  between	  the	  studies.	  Thus,	   to	  guide	  drug	  dosing	  in	  
CRRT-­‐receiving	   patients,	   either	   data	   and	   recommendations	   from	   those	   included	  
studies	   with	   adequate	   reporting	   and	   quality	   or	   a	   recently	   published	   individualized	  
drug	  dosing	  regimen44	  could	  be	  used.	  	  
 
The	  incidence	  rate	  of	  RRT-­‐treated	  AKI	  in	  the	  ICU	  can	  be	  used	  to	  plan	  future	  studies	  and	  
resource	   allocation.	   Given	   the	   observed	   increasing	   trend	   in	   the	   population-­‐based	  
incidence	  and	  the	  aging	  of	  the	  population,	  the	  need	  for	  RRT	  is	  also	  likely	  to	  increase	  in	  
the	  future.	  
 
Despite	  a	  high	  mortality	  rate	  compared	  to	  other	  patient	  groups	  treated	  in	  the	  ICU,	  the	  
outcome	   of	   RRT-­‐treated	   patients	   observed	   in	   this	   study	  was	   rather	   good	   relative	   to	  
other	   studies.	  Moreover,	   as	   the	  HRQOL	   of	   RRT	   patients	   did	   not	   clinically	   differ	   from	  
those	  without	  RRT	  and	  patients	  themselves	  perceived	  their	  HRQOL	  to	  be	  rather	  good	  
at	   six	  months,	   treating	   these	   critically	   ill	   patients	  with	  RRT	   seems	   to	   be	  worthwhile.	  
However,	  the	  cost-­‐effectiveness	  of	  the	  treatment	  needs	  to	  be	  evaluated.	  	  
 
RRT	   patients	   treated	   in	   large	   central	   and	   university	   hospitals	   had	   lower	   crude	   and	  
adjusted	  mortality	  rates	  than	  patients	  treated	  in	  small	  central	  hospitals.	  If	  the	  reasons	  
for	  this	  finding	  could	  be	  elucidated	  in-­‐depth	  and	  the	  results	  confirmed	  in	  other	  studies,	  
treatment	  of	  these	  patients	  or	  certain	  subgroups	  might	  be	  reasonable	  to	  concentrate	  to	  
larger	  centers.	  
 
The	   association	   of	   fluid	   overload	   at	   RRT	   initiation	   and	   worse	   outcome	   requires	  
confirmation	   in	   further	   studies.	   Fluid	   accumulation	   is	   potentially	  modifiable	   in	  many	  
patients,	   either	   initiating	   RRT	   before	   it	   develops,	   or	   using	   a	   more	   restrictive	   fluid	  





6.9 FUTURE PERSPECTIVES 
Only	   during	   the	   last	   decade,	   a	   reliable	   and	   validated	   definition	   of	   AKI	   has	   been	  
established,19,160	   with	   a	   recent	   update120	   thus	   enabling	   inter-­‐study	   comparisons	   and	  
enhancing	  the	  validity	  of	  research.	  RRT	  has	  largely	  evolved	  as	  well,	  and	  knowledge	  of	  
the	  best	  ways	  to	  provide	  RRT	  have	  markedly	  increased	  regarding	  adequate	  modality241	  
and	  dose	  of	  CRRT.204,187	  The	   care	  of	   this	   severely	   ill	   and	  heterogeneous	  group	  of	  AKI	  
patients	   requiring	   RRT	   is	   complex,	   and	  much	   remains	   to	   be	   elucidated,	   however.	   As	  
RRT	   itself	   is	  not	   a	   cure	   for	  AKI	  but	   a	   supportive	   treatment,	   gathering	  data	   regarding	  
underlying	  reasons	  for	  AKI,	  and	  finding	  measures	  to	  prevent	  and	  treat	  these	  reasons,	  is	  
of	   utmost	   importance.	   Recently,	   the	   concept	   of	   “permissive	   hypofiltration”	   was	  
introduced.38	  Its	  aim	  is	  to	  allow	  the	  injured	  kidney	  rest	  by	  initiating	  RRT	  early,	  instead	  
of	  increasing	  its	  work	  load	  with	  fluid	  challenges.38	  
In	   this	   study,	   RRT	   was	   found	   to	   be	   provided	   according	   to	   current	   international	  
recommendations	  nationwide,	  but	  it	  is	  likely	  that	  some	  regional	  variations	  in	  practices	  
still	   exist.	   Furthermore,	   variations	   in	   the	   population-­‐based	   incidence	   in	   different	  
hospital	   districts	  were	   found.	   Thus,	   the	   practices	   in	   different	   Finnish	   ICUs	   should	   be	  
studied	   in	  more	   detail.	   Uniform	   criteria	   for	   RRT	   initiation	   in	   Finnish	   ICUs	   should	   be	  
proposed.	  	  
Early	   initiation	  of	  RRT	   in	   terms	  of	   time	   from	   ICU	  admission	  may	  be	  one	  possible	  
explanation	   for	   the	  rather	  good	  outcome	   in	   this	  study.	  Thus	   far,	  good-­‐quality	  data	  on	  
timing	   of	   RRT	   are	   sparse,	   reflected	   by	   the	   inability	   of	   an	   international	   consensus	  
committee	  to	  provide	  a	  graded	  recommendation	  on	  RRT	  timing.120	  A	  multinational	  RCT	  
would	  be	  needed	  to	  adequately	  assess	  the	  timing	  of	  RRT	  and	  outcome.120	  Meanwhile,	  a	  
prognostic	  model	  for	  the	  need	  for	  RRT	  could	  be	  developed,	  including	  physiologic	  data	  
on	   ICU	   admission,	   underlying	   co-­‐morbidities,	   admission	   diagnosis,	   and	   several	   new	  
biomarkers,	  e.g.	  NGAL.	  A	  reliable	  prediction	  model	  for	  the	  need	  for	  RRT	  would	  provide	  
more	  tools	  for	  clinicians	  to	  initiate	  RRT	  early.	  Moreover,	  the	  ability	  of	  novel	  biomarkers	  
to	  predict	  90-­‐day	  mortality	  of	  RRT	  patients	  in	  general,	  and	  in	  subgroups	  such	  as	  severe	  
sepsis,	  could	  be	  evaluated.	  Regional	  citrate-­‐calcium	  anticoagulation	  was	  widely	  used	  in	  
the	   Finnish	   ICUs,	   and	   its	   possible	   favorable	   effect	   on	   outcome181	   warrants	   further	  
investigation.	  
The	   renal	   recovery	   rate	   found	   in	   this	   study	  was	   somewhat	   lower	   than	   in	   several	  
other	   reports.	   Future	   studies	   should	   address	   the	   reasons	   for	   this	   finding,	   and	  
subsequently,	  potential	  solutions.	  The	  kidney	  function	  of	   those	  patients	  who	  received	  
RRT	  during	  their	  ICU	  stay	  but	  initially	  recovered	  independent	  of	  RRT	  has	  been	  shown	  
to	  deteriorate	  over	  time	  more	  often	  than	  in	  patients	  not	  treated	  with	  RRT	  in	  the	  ICU.245	  
To	   diagnose	   the	   deteriorating	   kidney	   function	   of	   those	   patients	  with	   an	   initial	   renal	  
recovery,	  a	  routine	  clinical	   long-­‐term	  follow-­‐up	  should	  be	   implemented	  in	  the	  care	  of	  
these	  patients.	  The	  non-­‐recovery	  of	  kidney	  function	  causes	  increased	  costs.157	  Thus,	  for	  
a	   comprehensive	   analysis	   of	   the	   cost-­‐effectiveness	   of	   RRT	   treatment,	   a	   long-­‐term	  
follow-­‐up	   of	   these	   patients,	   including	   assessment	   of	   renal	   function	   and	   HRQOL,	   is	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needed.	   A	   national	   registry	   including	   all	   patients	   treated	  with	  RRT	   in	   the	   ICU	  would	  
facilitate	  the	  analysis	  of	  the	  cost-­‐effectiveness.	  
Results	   regarding	   presence	   of	   fluid	   overload	   at	   RRT	   initiation	   and	   its	   association	  
with	   increased	  risk	   for	  mortality	  are	   in	   line	  with	  several	  previous	  studies.16,25,89,227	  As	  
these	   all	   are	   observational	   studies,	   no	   causality	   with	   fluid	   overload	   and	   increased	  
mortality	  has	  been	  shown.	  To	  confirm	  the	  association	  of	  fluid	  overload	  with	  increased	  
risk	   for	   mortality,	   a	   multicenter	   RCT	   would	   be	   needed.	   It	   could	   also	   shed	   light	   into	  
whether	   fluid	   overload	   itself	   causes	   AKI	   or	   solely	   reflects	   the	   severity	   of	   illness.	  
Threshold	  values	  for	  degree	  of	  fluid	  accumulation	  as	  triggers	  for	  RRT	  initiation	  should	  
be	  evaluated	  as	  well.	  	  
Finding	  answers	  in	  the	  genetics	  for	  susceptibility	  to	  develop	  AKI,	  the	  need	  for	  RRT,	  
and	  renal	  recovery	  thereafter	  is	  a	  long-­‐term	  goal	  in	  the	  field	  of	  AKI	  research.	  Indeed,	  a	  
genetic	  susceptibility	  related	  to	  the	  presence	  of	  certain	  HLA	  alleles	  for	  decreased	  need	  




The	  following	  conclusions	  can	  be	  drawn	  on	  the	  basis	  of	  these	  studies:	  
 
1.	   The	   general	   quality	   of	   pharmacokinetic	   studies	   on	   CRRT-­‐receiving	   patients	  
measured	   with	   the	   Downs	   and	   Black	   quality	   score	   was	   moderate.	   The	   reporting	   of	  
CRRT	  and	  patient	  characteristics	  was	  poor,	  while	  the	  retrospectively	  calculated	  CRRT	  
dose	  used	  in	  these	  studies	  was	  according	  to	  the	  recommendations.	  	  
 
2.	  The	  population-­‐based	   incidence	  of	  RRT	  for	  AKI	  was	  19.4	  -­‐	  20.2	  per	  100	  000	  adults	  
per	  year,	  broadly	  in	  line	  with	  studies	  conducted	  in	  other	  regions.	  	  
 
3.	  RRT	  was	  initiated	  early	  compared	  to	  other	  reports,	  after	  a	  median	  of	  14	  hours	  from	  
ICU	  admission.	  A	  median	  of	  three	  indications	  were	  present	  at	  RRT	  initiation,	  the	  most	  
common	  being	  oliguria	  or	  anuria,	  high	  creatinine,	  and	  acidosis.	  In	  73%	  of	  patients,	  the	  
initial	   RRT	   modality	   was	   continuous.	   The	   CRRT	   dose	   adjusted	   for	   daily	   duration	   of	  
treatment	  was	  according	  to	  current	  recommendations.	  	  
 
4.	  The	  short-­‐term	  and	  long-­‐term	  mortality	  rates	  of	  patients	  receiving	  RRT	  were	  lower	  
than	  previously	  reported.	  Patients	  treated	  in	  small	  ICUs	  had	  higher	  crude	  and	  adjusted	  
hospital	  mortality	   rates	   compared	   to	   those	   treated	   in	   large	   ICUs.	   Patients	  with	   fluid	  
overload	  at	  RRT	  initiation	  had	  twice	  as	  high	  crude	  90-­‐day	  mortality	  rate	  than	  patients	  
without	   fluid	   overload,	   and	   the	   difference	   remained	   after	   adjusting	   for	   patient	   age,	  
severity	  of	   illness,	  presence	  of	  sepsis,	   time	   from	  ICU	  admission	   to	  RRT	   initiation,	  and	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